Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,700 | 2020-02-12 00:00:00 UTC | Gilead Sciences Looks Ready to Outpace AbbVie | ABBV | https://www.nasdaq.com/articles/gilead-sciences-looks-ready-to-outpace-abbvie-2020-02-12 | null | null | Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV) are two of the world's largest pharmaceutical stocks by market capitalization. AbbVie is the bigger of the two, at $139 billion to Gilead's $86 billion, and its stock value has grown significantly over the past year.
When considering the long-term prospects, is ei... | Its small portfolio may outpace AbbVie's larger one in the long run, especially with Humira due to expire in three years -- a risk for long-term investors, as the drug brought in roughly 45% of the company's revenue in 2019. AbbVie may provide a better short-term option with its six new assets, attractive valuation, an... | Both companies expect declining sales of HCV products, with AbbVie looking for a global total of about $2.5 billion in 2020 and Gilead sustaining its current sales. Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV) are two of the world's largest pharmaceutical stocks by market capitalization. AbbVie is the bigger ... | Sales of Gilead's products began to decline when AbbVie's HCV drug, Mavyret, was approved in 2017; changes to insurance coverage also reduced usage of HCV drugs, making them less lucrative overall. AbbVie's rise in the HCV market led Gilead to take the unexpected step of developing its own HCV generic drug, Epclusa, wh... | Both companies expect declining sales of HCV products, with AbbVie looking for a global total of about $2.5 billion in 2020 and Gilead sustaining its current sales. Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV) are two of the world's largest pharmaceutical stocks by market capitalization. AbbVie is the bigger ... |
24,701 | 2020-02-12 00:00:00 UTC | AbbVie Is a Dividend Growth Stock at a Bargain Price | ABBV | https://www.nasdaq.com/articles/abbvie-is-a-dividend-growth-stock-at-a-bargain-price-2020-02-12 | null | null | AbbVie (NYSE: ABBV) reported fourth-quarter earnings on Friday that were above consensus and the company raised its guidance for 2020. The results suggested that there was life after Humira, its mainstay immunology product, which is the world's best-selling drug.
On a day when the market was down 1%, AbbVie's shares ro... | The combined AbbVie/Allergan entity will rank fourth in overall revenues and third in operating cash flow, creating significant scale in an industry where the costs of delivering a new drug to the market is in excess of $2 billion and rising. With the stock trading at half the market price-to-earnings ratio, AbbVie rep... | AbbVie beat expectations and raised its guidance AbbVie's results were resoundingly positive. AbbVie (NYSE: ABBV) reported fourth-quarter earnings on Friday that were above consensus and the company raised its guidance for 2020. On a day when the market was down 1%, AbbVie's shares rose 5%. | With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor. Sales of AbbVie's hematological oncology drugs grew 39% to over $1.5 billion, driven by Imbruvica and Venclexta which combined for $5.5 billion in sales in 2019. ... | With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor. AbbVie (NYSE: ABBV) reported fourth-quarter earnings on Friday that were above consensus and the company raised its guidance for 2020. On a day when the market wa... |
24,702 | 2020-02-11 00:00:00 UTC | Tuesday's ETF with Unusual Volume: PPH | ABBV | https://www.nasdaq.com/articles/tuesdays-etf-with-unusual-volume%3A-pph-2020-02-11 | null | null | The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Tuesday, with over 80,000 shares traded versus three month average volume of about 50,000. Shares of PPH were up about 0.3% on the day.
Components of that ETF with the highest volume on Tuesday were Teva Pharmaceutical, trading up about 1.6% wi... | Abbvie is the component faring the best Tuesday, higher by about 2% on the day, while Mylan is lagging other components of the Pharmaceutical ETF, trading lower by about 1.4%. The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Tuesday, with over 80,000 shares traded versus three month average v... | Abbvie is the component faring the best Tuesday, higher by about 2% on the day, while Mylan is lagging other components of the Pharmaceutical ETF, trading lower by about 1.4%. The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Tuesday, with over 80,000 shares traded versus three month average v... | Abbvie is the component faring the best Tuesday, higher by about 2% on the day, while Mylan is lagging other components of the Pharmaceutical ETF, trading lower by about 1.4%. The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Tuesday, with over 80,000 shares traded versus three month average v... | Abbvie is the component faring the best Tuesday, higher by about 2% on the day, while Mylan is lagging other components of the Pharmaceutical ETF, trading lower by about 1.4%. The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Tuesday, with over 80,000 shares traded versus three month average v... |
24,703 | 2020-02-11 00:00:00 UTC | Better Buy: Pfizer vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy%3A-pfizer-vs.-abbvie-2020-02-11 | null | null | Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are both top-notch dividend stocks. At current levels, Pfizer's shares sport a ginormous yield of 3.99%. AbbVie, on the other hand, is the home of one of the industry's most generous payouts, with a forward-looking annualized yield of 5.11%.
Nonetheless, these two elite income... | Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are both top-notch dividend stocks. AbbVie, on the other hand, is the home of one of the industry's most generous payouts, with a forward-looking annualized yield of 5.11%. While AbbVie's shares have produced total returns on capital of 48% (when including dividends) over the ... | This transformational deal will immediately benefit AbbVie's top line, diversify its product portfolio, and perhaps result in another sizable increase to the drugmaker's dividend. Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are both top-notch dividend stocks. AbbVie, on the other hand, is the home of one of the industry... | Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are both top-notch dividend stocks. While AbbVie's shares have produced total returns on capital of 48% (when including dividends) over the last six months, Pfizer's stock has generated a far more modest return on capital of only 6% during the same period. AbbVie, on the other... | Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are both top-notch dividend stocks. AbbVie, on the other hand, is the home of one of the industry's most generous payouts, with a forward-looking annualized yield of 5.11%. While AbbVie's shares have produced total returns on capital of 48% (when including dividends) over the ... |
24,704 | 2020-02-11 00:00:00 UTC | Is Takeda Pharmaceutical Company Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-takeda-pharmaceutical-company-stock-a-buy-2020-02-11 | null | null | There probably aren't too many companies listed on the New York Stock Exchange with an operating history going back over 230 years that are virtually unknown to U.S. investors.
But that's true of Takeda Pharmaceutical Company (NYSE: TAK), Japan's largest pharmaceutical company, which was founded in 1781 and listed its ... | Entyvio sales are growing at 35%, and beat AbbVie's mega-blockbuster Humira in a head-to-head trial in UC last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie and Seattle Genetics. Takeda has partnerships with a number of U.S. pharmaceutical companies, and made hea... | Entyvio sales are growing at 35%, and beat AbbVie's mega-blockbuster Humira in a head-to-head trial in UC last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie and Seattle Genetics. But that's true of Takeda Pharmaceutical Company (NYSE: TAK), Japan's largest pharma... | Entyvio sales are growing at 35%, and beat AbbVie's mega-blockbuster Humira in a head-to-head trial in UC last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie and Seattle Genetics. But that's true of Takeda Pharmaceutical Company (NYSE: TAK), Japan's largest pharma... | Entyvio sales are growing at 35%, and beat AbbVie's mega-blockbuster Humira in a head-to-head trial in UC last year. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie and Seattle Genetics. Takeda has partnerships with a number of U.S. pharmaceutical companies, and made hea... |
24,705 | 2020-02-10 00:00:00 UTC | Allergan Reports Fourth-Quarter 2019 Results That Plow Past Expectations | ABBV | https://www.nasdaq.com/articles/allergan-reports-fourth-quarter-2019-results-that-plow-past-expectations-2020-02-10 | null | null | Shares of Allergan (NYSE: AGN) received a slight bump on Monday morning in response to a fourth-quarter earnings report that exceeded expectations on the top and bottom lines. Shares of AbbVie (NYSE: ABBV), a larger drugmaker with plans to buy Allergan in the first quarter, also ticked up slightly.
Allergan's total rev... | As the company's ability to maintain market exclusivity for cyclosporine-containing eye drops erodes, AbbVie can probably expect the Restasis brand to decline further. Shares of AbbVie (NYSE: ABBV), a larger drugmaker with plans to buy Allergan in the first quarter, also ticked up slightly. Looking ahead AbbVie already... | Shares of AbbVie (NYSE: ABBV), a larger drugmaker with plans to buy Allergan in the first quarter, also ticked up slightly. As the company's ability to maintain market exclusivity for cyclosporine-containing eye drops erodes, AbbVie can probably expect the Restasis brand to decline further. Looking ahead AbbVie already... | Shares of AbbVie (NYSE: ABBV), a larger drugmaker with plans to buy Allergan in the first quarter, also ticked up slightly. As the company's ability to maintain market exclusivity for cyclosporine-containing eye drops erodes, AbbVie can probably expect the Restasis brand to decline further. Looking ahead AbbVie already... | Shares of AbbVie (NYSE: ABBV), a larger drugmaker with plans to buy Allergan in the first quarter, also ticked up slightly. As the company's ability to maintain market exclusivity for cyclosporine-containing eye drops erodes, AbbVie can probably expect the Restasis brand to decline further. Looking ahead AbbVie already... |
24,706 | 2020-02-10 00:00:00 UTC | How Allergan Beat Estimates in What's Likely Its Last Quarterly Update | ABBV | https://www.nasdaq.com/articles/how-allergan-beat-estimates-in-whats-likely-its-last-quarterly-update-2020-02-10 | null | null | Allergan (NYSE: AGN) entered 2020 with a lot of momentum. AbbVie's (NYSE: ABBV) announcement of its plans to acquire Allergan gave the stock a big boost. That news was so great that investors didn't care that Allergan delivered less-than-exciting third-quarter results in November.
But there were some things to energize... | AbbVie's (NYSE: ABBV) announcement of its plans to acquire Allergan gave the stock a big boost. Looking ahead By far the main thing to look forward to with Allergan is the anticipated close of AbbVie's acquisition of the company later in the first quarter of 2020. This deal will make current Allergan shareholders owner... | AbbVie's (NYSE: ABBV) announcement of its plans to acquire Allergan gave the stock a big boost. Looking ahead By far the main thing to look forward to with Allergan is the anticipated close of AbbVie's acquisition of the company later in the first quarter of 2020. This deal will make current Allergan shareholders owner... | AbbVie's (NYSE: ABBV) announcement of its plans to acquire Allergan gave the stock a big boost. Looking ahead By far the main thing to look forward to with Allergan is the anticipated close of AbbVie's acquisition of the company later in the first quarter of 2020. This deal will make current Allergan shareholders owner... | AbbVie's (NYSE: ABBV) announcement of its plans to acquire Allergan gave the stock a big boost. Looking ahead By far the main thing to look forward to with Allergan is the anticipated close of AbbVie's acquisition of the company later in the first quarter of 2020. This deal will make current Allergan shareholders owner... |
24,707 | 2020-02-10 00:00:00 UTC | AbbVie Reaches Analyst Target Price | ABBV | https://www.nasdaq.com/articles/abbvie-reaches-analyst-target-price-2020-02-10 | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.88, changing hands for $92.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a h... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.88, changing hands for $92.29/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.88, changing hands for $92.29/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | And so with ABBV crossing above that average target price of $90.88/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $90.88 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is ti... | There are 8 different analyst targets contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.88, changing hands for $92.29/share. But the whole reason t... |
24,708 | 2020-02-10 00:00:00 UTC | Monday's ETF with Unusual Volume: PJP | ABBV | https://www.nasdaq.com/articles/mondays-etf-with-unusual-volume%3A-pjp-2020-02-10 | null | null | The Invesco Dynamic Pharmaceuticals ETF is seeing unusually high volume in afternoon trading Monday, with over 75,000 shares traded versus three month average volume of about 36,000. Shares of PJP were up about 0.5% on the day.
Components of that ETF with the highest volume on Monday were Gilead Sciences, trading down ... | Components of that ETF with the highest volume on Monday were Gilead Sciences, trading down about 1.4% with over 7.8 million shares changing hands so far this session, and Abbvie, up about 2.4% on volume of over 7.4 million shares. The Invesco Dynamic Pharmaceuticals ETF is seeing unusually high volume in afternoon tra... | Components of that ETF with the highest volume on Monday were Gilead Sciences, trading down about 1.4% with over 7.8 million shares changing hands so far this session, and Abbvie, up about 2.4% on volume of over 7.4 million shares. The Invesco Dynamic Pharmaceuticals ETF is seeing unusually high volume in afternoon tra... | Components of that ETF with the highest volume on Monday were Gilead Sciences, trading down about 1.4% with over 7.8 million shares changing hands so far this session, and Abbvie, up about 2.4% on volume of over 7.4 million shares. The Invesco Dynamic Pharmaceuticals ETF is seeing unusually high volume in afternoon tra... | Components of that ETF with the highest volume on Monday were Gilead Sciences, trading down about 1.4% with over 7.8 million shares changing hands so far this session, and Abbvie, up about 2.4% on volume of over 7.4 million shares. Pacira Biosciences is the component faring the best Monday, up by about 5.2% on the day,... |
24,709 | 2020-02-07 00:00:00 UTC | AbbVie Inc (ABBV) Q4 2019 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-q4-2019-earnings-call-transcript-2020-02-07 | null | null | Image source: The Motley Fool.
AbbVie Inc (NYSE: ABBV)
Q4 2019 Earnings Call
Feb 7, 2020, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie Fourth Quarter 2019 Earnings Conference Call. [Operator I... | The most advanced of these are ABBV-155, which uses a B7-H3 targeting antibody to deliver a novel high potency BCL-XL warhead to solid tumors, and ABBV-621, which is designed to induce apoptosis by clustering trail and apoptosis-inducing ligand on the surface of cancer cells. AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Ca... | Allergan will provide AbbVie with highly valuable on-market assets with leadership positions across additional attractive growth segments, including new growth platforms in aesthetics and CNS neuroscience. Operator [Operator Closing Remarks] Duration: 80 minutes Call participants: Liz Shea -- Vice President of Investor... | We will also see proof of concept data this year from several other early stage assets in our immunology portfolio, including data for ABBV-599, our JAK/BTK program, and ABBV-323, our CD40 antagonist program, which are both targeting multiple pathogenic nodes that are thought to play important roles in diseases such as... | Operator [Operator Closing Remarks] Duration: 80 minutes Call participants: Liz Shea -- Vice President of Investor Relations Richard A. Gonzalez -- Chairman of the Board and Chief Executive Officer Michael E. Severino -- Vice Chairman and President Robert A. Michael -- Executive Vice President and Chief Financial Offic... |
24,710 | 2020-02-07 00:00:00 UTC | AbbVie Q4 19 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q4-19-earnings-conference-call-at-9%3A00-am-et-2020-02-07-0 | null | null | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result.
To access the live webcast, log on at https://investors.abbvie.com/investor-overview
The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... |
24,711 | 2020-02-07 00:00:00 UTC | AbbVie Q4 19 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q4-19-earnings-conference-call-at-9%3A00-am-et-2020-02-07 | null | null | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result.
To access the live webcast, log on at https://investors.abbvie.com/investor-overview
The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie Inc. (ABBV) will host a conference call at 9:00 AM ET on Feb. 7, 2020, to discuss its Q4 19 earnings result. To access the live webcast, log on at https://investors.abbvie.com/investor-overview The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... |
24,712 | 2020-02-07 00:00:00 UTC | AbbVie Q4 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q4-adjusted-earnings-beat-estimates-2020-02-07 | null | null | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV):
-Earnings: $2.80 billion in Q4 vs. -$1.83 billion in the same period last year. -EPS: $1.88 in Q4 vs. -$1.23 in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.29 billion or $2.21 per share for the period. -Analysts pr... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $2.80 billion in Q4 vs. -$1.83 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.29 billion or $2.21 per share for the period. The views and opinions expressed herein are the views and opinions of t... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $2.80 billion in Q4 vs. -$1.83 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.29 billion or $2.21 per share for the period. -Analysts projected $2.19 per share -Revenue: $8.70 billion in Q4 vs. $... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $2.80 billion in Q4 vs. -$1.83 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.29 billion or $2.21 per share for the period. -Analysts projected $2.19 per share -Revenue: $8.70 billion in Q4 vs. $... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $2.80 billion in Q4 vs. -$1.83 billion in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.29 billion or $2.21 per share for the period. -Analysts projected $2.19 per share -Revenue: $8.70 billion in Q4 vs. $... |
24,713 | 2020-02-07 00:00:00 UTC | AbbVie Reports Estimate-Beating Fourth-Quarter Earnings Results | ABBV | https://www.nasdaq.com/articles/abbvie-reports-estimate-beating-fourth-quarter-earnings-results-2020-02-07 | null | null | AbbVie (NYSE: ABBV) recently delivered an encouraging earnings report for the last three months of 2019. Revenue that grew 2% year over year to $8.7 billion surpassed consensus estimates by $20 million. On the bottom line, adjusted earnings grew 13% to $2.21 per share which was $0.02 more than the average Wall Street a... | In the fourth quarter, AbbVie still leaned on Humira for 56% of total revenue but Skyrizi and Rinvoq will lower the company's reliance on the aging blockbuster much further in 2020. AbbVie (NYSE: ABBV) recently delivered an encouraging earnings report for the last three months of 2019. Successful new drug launches Seve... | In the fourth quarter, AbbVie still leaned on Humira for 56% of total revenue but Skyrizi and Rinvoq will lower the company's reliance on the aging blockbuster much further in 2020. AbbVie (NYSE: ABBV) recently delivered an encouraging earnings report for the last three months of 2019. Successful new drug launches Seve... | Successful new drug launches Several of the investments AbbVie has made to offset Humira sales have been so successful the company expects 8% growth in 2020 on the top and bottom lines, before factoring in the impending acquisition of Allergan (NYSE: AGN). AbbVie (NYSE: ABBV) recently delivered an encouraging earnings ... | In the fourth quarter, AbbVie still leaned on Humira for 56% of total revenue but Skyrizi and Rinvoq will lower the company's reliance on the aging blockbuster much further in 2020. AbbVie (NYSE: ABBV) recently delivered an encouraging earnings report for the last three months of 2019. Successful new drug launches Seve... |
24,714 | 2020-02-07 00:00:00 UTC | AbbVie Issues FY20 Outlook - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-issues-fy20-outlook-quick-facts-2020-02-07 | null | null | (RTTNews) - AbbVie (ABBV) said, for fiscal 2020, the company projects standalone adjusted EPS of $9.61 to $9.71, a growth of 8.1 percent at the midpoint. The company noted that its standalone guidance excludes $1.95 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjust... | (RTTNews) - AbbVie (ABBV) said, for fiscal 2020, the company projects standalone adjusted EPS of $9.61 to $9.71, a growth of 8.1 percent at the midpoint. Shares of AbbVie were up 3% in pre-market trade on Friday. The company noted that its standalone guidance excludes $1.95 per share of intangible asset amortization ex... | (RTTNews) - AbbVie (ABBV) said, for fiscal 2020, the company projects standalone adjusted EPS of $9.61 to $9.71, a growth of 8.1 percent at the midpoint. Shares of AbbVie were up 3% in pre-market trade on Friday. The company expects standalone revenue growth approaching 8.0 percent on an operational basis. | (RTTNews) - AbbVie (ABBV) said, for fiscal 2020, the company projects standalone adjusted EPS of $9.61 to $9.71, a growth of 8.1 percent at the midpoint. Shares of AbbVie were up 3% in pre-market trade on Friday. Analysts polled by Thomson Reuters expect the company to report profit per share of $9.48. | (RTTNews) - AbbVie (ABBV) said, for fiscal 2020, the company projects standalone adjusted EPS of $9.61 to $9.71, a growth of 8.1 percent at the midpoint. Shares of AbbVie were up 3% in pre-market trade on Friday. The company expects standalone revenue growth approaching 8.0 percent on an operational basis. |
24,715 | 2020-02-07 00:00:00 UTC | Stock Alert: AbbVie Ascends 5% | ABBV | https://www.nasdaq.com/articles/stock-alert%3A-abbvie-ascends-5-2020-02-07 | null | null | (RTTNews) - Shares of drugmaker AbbVie Inc. (ABBV) are climbing more than 5% on Friday morning after the company reported better-than-expected fourth-quarter earnings and a strong full-year 2020 outlook. The stock is currently trading at $91.93, nearing its 52-week high of $92.19.
Net income in the fourth quarter was $... | (RTTNews) - Shares of drugmaker AbbVie Inc. (ABBV) are climbing more than 5% on Friday morning after the company reported better-than-expected fourth-quarter earnings and a strong full-year 2020 outlook. For the full-year, AbbVie expects to deliver standalone adjusted EPS in the range of $9.61 to $9.71 and standalone r... | For the full-year, AbbVie expects to deliver standalone adjusted EPS in the range of $9.61 to $9.71 and standalone revenue growth of approximately 8.0 percent. (RTTNews) - Shares of drugmaker AbbVie Inc. (ABBV) are climbing more than 5% on Friday morning after the company reported better-than-expected fourth-quarter ea... | (RTTNews) - Shares of drugmaker AbbVie Inc. (ABBV) are climbing more than 5% on Friday morning after the company reported better-than-expected fourth-quarter earnings and a strong full-year 2020 outlook. For the full-year, AbbVie expects to deliver standalone adjusted EPS in the range of $9.61 to $9.71 and standalone r... | (RTTNews) - Shares of drugmaker AbbVie Inc. (ABBV) are climbing more than 5% on Friday morning after the company reported better-than-expected fourth-quarter earnings and a strong full-year 2020 outlook. For the full-year, AbbVie expects to deliver standalone adjusted EPS in the range of $9.61 to $9.71 and standalone r... |
24,716 | 2020-02-06 00:00:00 UTC | 5 Total Yield Dividend Stocks That Offer Attractive Returns | ABBV | https://www.nasdaq.com/articles/5-total-yield-dividend-stocks-that-offer-attractive-returns-2020-02-06 | null | null | I like high-yield dividend stocks that also have the ability to buy back their shares. These are called total yield dividend stocks. They offer investors attractive total returns.
Source: Shutterstock
The amount of share buybacks (also referred to as ) during the year divided by the market value equals the buyback yiel... | Its purchase of Allergan, expected to close shortly, will boost earnings and dividends and push AbbVieâÂÂs stock higher. AbbVie is losing its patent protection on Humira, a rheumatoid arthritis treatment that accounts for more than half of AbbVieâÂÂs revenue. High Total Yield Dividend Stocks: AbbVie (ABBV) Divide... | High Total Yield Dividend Stocks: AbbVie (ABBV) Dividend Yield: 5.45% Source: Mark R. Hake, CFA Buyback Yield: 2.87% Total Yield: 8.32% AbbVie (NYSE:) is a drug company. Its purchase of Allergan, expected to close shortly, will boost earnings and dividends and push AbbVieâÂÂs stock higher. AbbVie is losing its paten... | High Total Yield Dividend Stocks: AbbVie (ABBV) Dividend Yield: 5.45% Source: Mark R. Hake, CFA Buyback Yield: 2.87% Total Yield: 8.32% AbbVie (NYSE:) is a drug company. Its purchase of Allergan, expected to close shortly, will boost earnings and dividends and push AbbVieâÂÂs stock higher. AbbVie is losing its paten... | High Total Yield Dividend Stocks: AbbVie (ABBV) Dividend Yield: 5.45% Source: Mark R. Hake, CFA Buyback Yield: 2.87% Total Yield: 8.32% AbbVie (NYSE:) is a drug company. Its purchase of Allergan, expected to close shortly, will boost earnings and dividends and push AbbVieâÂÂs stock higher. AbbVie is losing its paten... |
24,717 | 2020-02-06 00:00:00 UTC | Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda | ABBV | https://www.nasdaq.com/articles/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-2020-02-06 | null | null | When it comes to cancer, immunology is the story of the decade.
Source: JHVEPhoto / Shutterstock.com
James Allison and Tasuku Honjo shared the for their discovery that the immune system could be tuned up to fight cancer. MerckâÂÂs (NYSE:) Keytruda became a blockbuster drug on the strength of that science.
Keytrudaâ... | It is expected to soon become the best-selling drug in the world, topping , the immunosuppressant from AbbVie (NYSE:) often used to treat arthritis. Source: JHVEPhoto / Shutterstock.com James Allison and Tasuku Honjo shared the for their discovery that the immune system could be tuned up to fight cancer. Among the prod... | It is expected to soon become the best-selling drug in the world, topping , the immunosuppressant from AbbVie (NYSE:) often used to treat arthritis. KeytrudaâÂÂs 2019 sales of $11.1 billion are expected to double in five years, , so Merck CEO Ken Frazier thinks it makes sense to spin out slower growing Merck units a... | It is expected to soon become the best-selling drug in the world, topping , the immunosuppressant from AbbVie (NYSE:) often used to treat arthritis. KeytrudaâÂÂs 2019 sales of $11.1 billion are expected to double in five years, , so Merck CEO Ken Frazier thinks it makes sense to spin out slower growing Merck units a... | It is expected to soon become the best-selling drug in the world, topping , the immunosuppressant from AbbVie (NYSE:) often used to treat arthritis. MerckâÂÂs (NYSE:) Keytruda became a blockbuster drug on the strength of that science. Net income of $2.4 billion, 92 cents per share, on revenue of $11.9 billion sent s... |
24,718 | 2020-02-05 00:00:00 UTC | AbbVie: RINVOQ Meets Endpoints In Phase 3 Study In Psoriatic Arthritis | ABBV | https://www.nasdaq.com/articles/abbvie%3A-rinvoq-meets-endpoints-in-phase-3-study-in-psoriatic-arthritis-2020-02-05 | null | null | (RTTNews) - AbbVie (ABBV) said, in a phase 3 SELECT-PsA 1 clinical trial, both doses of RINVOQTM (upadacitinib; 15 mg and 30 mg) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis. The 30 mg dose of RINVOQ recorded superiority to adalimumab in terms of... | (RTTNews) - AbbVie (ABBV) said, in a phase 3 SELECT-PsA 1 clinical trial, both doses of RINVOQTM (upadacitinib; 15 mg and 30 mg) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis. RAbbVie will present the results from the SELECT-PsA 1 study at a futur... | (RTTNews) - AbbVie (ABBV) said, in a phase 3 SELECT-PsA 1 clinical trial, both doses of RINVOQTM (upadacitinib; 15 mg and 30 mg) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis. RAbbVie will present the results from the SELECT-PsA 1 study at a futur... | (RTTNews) - AbbVie (ABBV) said, in a phase 3 SELECT-PsA 1 clinical trial, both doses of RINVOQTM (upadacitinib; 15 mg and 30 mg) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis. RAbbVie will present the results from the SELECT-PsA 1 study at a futur... | (RTTNews) - AbbVie (ABBV) said, in a phase 3 SELECT-PsA 1 clinical trial, both doses of RINVOQTM (upadacitinib; 15 mg and 30 mg) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis. RAbbVie will present the results from the SELECT-PsA 1 study at a futur... |
24,719 | 2020-02-05 00:00:00 UTC | How Neurocrine Biosciences Crushed It in Q4 | ABBV | https://www.nasdaq.com/articles/how-neurocrine-biosciences-crushed-it-in-q4-2020-02-05 | null | null | No one can complain about Neurocrine Biosciences' (NASDAQ: NBIX) stock performance in 2019. The biotech's shares skyrocketed more than 50% last year. So far in 2020, though, Neurocrine hasn't given investors many reasons to cheer. Until now.
Neurocrine announced its 2019 fourth-quarter and full-year results after the m... | Those three approved treatments referred to by Gorman include Ingrezza and Orilissa, which Neurocrine licensed to AbbVie. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. The company announced net income of $34 million, or $0.35 per share, based on generally accepted... | Those three approved treatments referred to by Gorman include Ingrezza and Orilissa, which Neurocrine licensed to AbbVie. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. No one can complain about Neurocrine Biosciences' (NASDAQ: NBIX) stock performance in 2019. | Those three approved treatments referred to by Gorman include Ingrezza and Orilissa, which Neurocrine licensed to AbbVie. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. Neurocrine posted Q4 adjusted net income of $102.2 million, or $1.05 per share. | Those three approved treatments referred to by Gorman include Ingrezza and Orilissa, which Neurocrine licensed to AbbVie. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. This reflected a significant improvement from GAAP earnings of $18 million, or $0.19 per share, ... |
24,720 | 2020-02-05 00:00:00 UTC | AbbVie Reports Successful Trial Results for Arthritis Drug | ABBV | https://www.nasdaq.com/articles/abbvie-reports-successful-trial-results-for-arthritis-drug-2020-02-05 | null | null | AbbVie (NYSE: ABBV) reported that its new immunology drug Rinvoq (upadacitinib) successfully met primary and secondary endpoints in a registrational trial for treatment of psoriatic arthritis, clearing the way for the company to file a new drug application (NDA) for the indication later this year.
In the study of 1,705... | AbbVie (NYSE: ABBV) reported that its new immunology drug Rinvoq (upadacitinib) successfully met primary and secondary endpoints in a registrational trial for treatment of psoriatic arthritis, clearing the way for the company to file a new drug application (NDA) for the indication later this year. The trial also compar... | AbbVie (NYSE: ABBV) reported that its new immunology drug Rinvoq (upadacitinib) successfully met primary and secondary endpoints in a registrational trial for treatment of psoriatic arthritis, clearing the way for the company to file a new drug application (NDA) for the indication later this year. The trial also compar... | AbbVie (NYSE: ABBV) reported that its new immunology drug Rinvoq (upadacitinib) successfully met primary and secondary endpoints in a registrational trial for treatment of psoriatic arthritis, clearing the way for the company to file a new drug application (NDA) for the indication later this year. 10 stocks we like bet... | The trial also compared Rinvoq to AbbVie's Humira, the world's top-selling drug that's under threat from biosimilars, and those results may not be as conclusive as the company was hoping. AbbVie (NYSE: ABBV) reported that its new immunology drug Rinvoq (upadacitinib) successfully met primary and secondary endpoints in ... |
24,721 | 2020-02-04 00:00:00 UTC | FDA Approves Emergency Use of Coronavirus Test | ABBV | https://www.nasdaq.com/articles/fda-approves-emergency-use-of-coronavirus-test-2020-02-05 | null | null | The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus test.
Developed by the Centers for Disease Control and Prevention (CDC), the 2019-nCoV Real-Time RT-PCR diagnostic panel is a test that has been limited only to CDC laboratories... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. Although the threat of an epidemic in the U.S. remains low according to the FDA, it was still declared a public health emergency by the Trump a... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus ... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus ... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus ... |
24,722 | 2020-02-04 00:00:00 UTC | FDA Approves Emergency Use of Coronavirus Test | ABBV | https://www.nasdaq.com/articles/fda-approves-emergency-use-of-coronavirus-test-2020-02-05-0 | null | null | The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus test.
Developed by the Centers for Disease Control and Prevention (CDC), the 2019-nCoV Real-Time RT-PCR diagnostic panel is a test that has been limited only to CDC laboratories... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. Although the threat of an epidemic in the U.S. remains low according to the FDA, it was still declared a public health emergency by the Trump a... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus ... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus ... | Inovio Pharmaceuticals and Moderna are two companies competing with not just the likes of Gilead, but also against other healthcare giants such as Johnson & Johnson and AbbVie. The U.S. Food and Drug Administration (FDA) released a press release Tuesday afternoon in which it approved the emergency use of a coronavirus ... |
24,723 | 2020-02-03 00:00:00 UTC | Gilead's Ebola Drug Shows Positive Signs in Treating Coronavirus | ABBV | https://www.nasdaq.com/articles/gileads-ebola-drug-shows-positive-signs-in-treating-coronavirus-2020-02-03 | null | null | Gilead Sciences (NASDAQ: GILD) shot up as much as 13% on the news that its failed Ebola drug, remdesivir, showed promising initial signs of helping patients with the coronavirus. In an official statement before the weekend, the company announced it was working together with U.S. and Chinese health regulators to see whe... | AbbVie stated it saw positive results by mixing two HIV medications with another drug called Tamiflu. Gilead Sciences (NASDAQ: GILD) shot up as much as 13% on the news that its failed Ebola drug, remdesivir, showed promising initial signs of helping patients with the coronavirus. In an official statement before the wee... | AbbVie stated it saw positive results by mixing two HIV medications with another drug called Tamiflu. Remdesivir was also tested on one U.S. coronavirus patient prior to the weekend, who showed an impressive improvement in symptoms following a single dose. After all, the newsletter they have run for over a decade, Motl... | AbbVie stated it saw positive results by mixing two HIV medications with another drug called Tamiflu. Gilead Sciences (NASDAQ: GILD) shot up as much as 13% on the news that its failed Ebola drug, remdesivir, showed promising initial signs of helping patients with the coronavirus. 10 stocks we like better than Gilead Sc... | AbbVie stated it saw positive results by mixing two HIV medications with another drug called Tamiflu. Remdesivir was also tested on one U.S. coronavirus patient prior to the weekend, who showed an impressive improvement in symptoms following a single dose. The Motley Fool owns shares of and recommends Gilead Sciences. |
24,724 | 2020-02-03 00:00:00 UTC | Invesco S&P Ultra Dividend Revenue ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/invesco-sp-ultra-dividend-revenue-etf-experiences-big-inflow-2020-02-03 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P Ultra Dividend Revenue ETF (Symbol: RDIV) where we have detected an approximate $208.2 million dollar inflow -- that's a 13.6% increase week over week in outstanding units (from ... | Among the largest underlying components of RDIV, in trading today Cardinal Health, Inc. (Symbol: CAH) is up about 1.6%, International Business Machines Corp (Symbol: IBM) is up about 2.3%, and AbbVie Inc (Symbol: ABBV) is up by about 1.7%. For a complete list of holdings, visit the RDIV Holdings page » The chart below ... | Among the largest underlying components of RDIV, in trading today Cardinal Health, Inc. (Symbol: CAH) is up about 1.6%, International Business Machines Corp (Symbol: IBM) is up about 2.3%, and AbbVie Inc (Symbol: ABBV) is up by about 1.7%. For a complete list of holdings, visit the RDIV Holdings page » The chart below ... | Among the largest underlying components of RDIV, in trading today Cardinal Health, Inc. (Symbol: CAH) is up about 1.6%, International Business Machines Corp (Symbol: IBM) is up about 2.3%, and AbbVie Inc (Symbol: ABBV) is up by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of... | Among the largest underlying components of RDIV, in trading today Cardinal Health, Inc. (Symbol: CAH) is up about 1.6%, International Business Machines Corp (Symbol: IBM) is up about 2.3%, and AbbVie Inc (Symbol: ABBV) is up by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of... |
24,725 | 2020-02-03 00:00:00 UTC | 3 Growth Stocks for Low Risk Investors | ABBV | https://www.nasdaq.com/articles/3-growth-stocks-for-low-risk-investors-2020-02-03 | null | null | Major market benchmarks hit new highs in early 2020 as a wave of optimism swept over the market. But sentiment can turn sharply at any moment, as investors are seeing recently with worries about the coronavirus outbreak, and conservative investors may be wondering whether it's worth the risk to own growth stocks right ... | AbbVie is the maker of the top-selling drug in the world, Humira, but that tremendous positive has turned into a negative for investors as competition from biosimilars has started to eat away at sales. SVB Financial Group (NASDAQ: SIVB), AbbVie (NYSE: ABBV), and NextEra Energy (NYSE: NEE) all offer opportunities for lo... | SVB Financial Group (NASDAQ: SIVB), AbbVie (NYSE: ABBV), and NextEra Energy (NYSE: NEE) all offer opportunities for low-risk investors to get long-term growth in their portfolios without losing sleep. AbbVie The healthcare sector is a good place for conservative investors to find stocks that have growth that holds up i... | SVB Financial Group (NASDAQ: SIVB), AbbVie (NYSE: ABBV), and NextEra Energy (NYSE: NEE) all offer opportunities for low-risk investors to get long-term growth in their portfolios without losing sleep. AbbVie The healthcare sector is a good place for conservative investors to find stocks that have growth that holds up i... | SVB Financial Group (NASDAQ: SIVB), AbbVie (NYSE: ABBV), and NextEra Energy (NYSE: NEE) all offer opportunities for low-risk investors to get long-term growth in their portfolios without losing sleep. AbbVie The healthcare sector is a good place for conservative investors to find stocks that have growth that holds up i... |
24,726 | 2020-02-02 00:00:00 UTC | Where Will Vertex Pharmaceuticals Be in 10 Years? | ABBV | https://www.nasdaq.com/articles/where-will-vertex-pharmaceuticals-be-in-10-years-2020-02-02 | null | null | It's easy to grasp how Vertex Pharmaceuticals (NASDAQ: VRTX) got to where it is today. A decade ago, the biotech's market cap hovered around $8 billion. Vertex's lead pipeline candidate was hepatitis C virus (HCV) drug telaprevir, which went on to win FDA approval in 2011. The drug was marketed under the brand name Inc... | AbbVie is evaluating a triple-drug CF combo that it picked up from Galapagos in a phase 1 clinical study, but it's way behind Vertex. Even if AbbVie's drug proves to be successful, it would at best be several years before the drug could win approval. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith... | AbbVie is evaluating a triple-drug CF combo that it picked up from Galapagos in a phase 1 clinical study, but it's way behind Vertex. Even if AbbVie's drug proves to be successful, it would at best be several years before the drug could win approval. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith... | AbbVie is evaluating a triple-drug CF combo that it picked up from Galapagos in a phase 1 clinical study, but it's way behind Vertex. Even if AbbVie's drug proves to be successful, it would at best be several years before the drug could win approval. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith... | AbbVie is evaluating a triple-drug CF combo that it picked up from Galapagos in a phase 1 clinical study, but it's way behind Vertex. Even if AbbVie's drug proves to be successful, it would at best be several years before the drug could win approval. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith... |
24,727 | 2020-01-31 00:00:00 UTC | Eli Lilly Launches a New Migraine Drug | ABBV | https://www.nasdaq.com/articles/eli-lilly-launches-a-new-migraine-drug-2020-01-31 | null | null | Eli Lilly (NYSE: LLY) launched its new pill for the acute treatment of migraines Friday after the Drug Enforcement Administration completed its review of the drug and classified it as having a low potential for abuse or dependence. Reyvow is the first drug of a new class, and treats not only pain, but sensitivity to l... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Reyvow was approved by th... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Eli Lilly (NYSE: LLY) lau... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Eli Lilly (NYSE: LLY) lau... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Eli Lilly (NYSE: LLY) lau... |
24,728 | 2020-01-31 00:00:00 UTC | AbbVie Gets Good News on 2 Drugs from EU Committee | ABBV | https://www.nasdaq.com/articles/abbvie-gets-good-news-on-2-drugs-from-eu-committee-2020-01-31 | null | null | The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the agency expand its marketing authorization for two drugs from AbbVie (NYSE: ABBV): chronic lymphocytic leukemia (CLL) treatment Venclyxto and hepatitis C drug Maviret.
Venclyxto, which targets a protein called ... | The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the agency expand its marketing authorization for two drugs from AbbVie (NYSE: ABBV): chronic lymphocytic leukemia (CLL) treatment Venclyxto and hepatitis C drug Maviret. That would help Abbvie compete against Gil... | The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the agency expand its marketing authorization for two drugs from AbbVie (NYSE: ABBV): chronic lymphocytic leukemia (CLL) treatment Venclyxto and hepatitis C drug Maviret. That would help Abbvie compete against Gil... | The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the agency expand its marketing authorization for two drugs from AbbVie (NYSE: ABBV): chronic lymphocytic leukemia (CLL) treatment Venclyxto and hepatitis C drug Maviret. That would help Abbvie compete against Gil... | The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the agency expand its marketing authorization for two drugs from AbbVie (NYSE: ABBV): chronic lymphocytic leukemia (CLL) treatment Venclyxto and hepatitis C drug Maviret. That would help Abbvie compete against Gil... |
24,729 | 2020-01-31 00:00:00 UTC | AbbVie Reports CHMP Positive Opinion For VENCLYXTO - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-reports-chmp-positive-opinion-for-venclyxto-quick-facts-2020-01-31 | null | null | (RTTNews) - AbbVie (ABBV) said CHMP, the Committee of the European Medicines Agency, has granted a positive opinion for VENCLYXTO (venetoclax) in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia who were previously untreated. The final decision by European Commission is expe... | (RTTNews) - AbbVie (ABBV) said CHMP, the Committee of the European Medicines Agency, has granted a positive opinion for VENCLYXTO (venetoclax) in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia who were previously untreated. VENCLYXTO is being developed by AbbVie and Roche.... | (RTTNews) - AbbVie (ABBV) said CHMP, the Committee of the European Medicines Agency, has granted a positive opinion for VENCLYXTO (venetoclax) in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia who were previously untreated. VENCLYXTO is being developed by AbbVie and Roche.... | (RTTNews) - AbbVie (ABBV) said CHMP, the Committee of the European Medicines Agency, has granted a positive opinion for VENCLYXTO (venetoclax) in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia who were previously untreated. It is jointly commercialized by AbbVie and Genent... | (RTTNews) - AbbVie (ABBV) said CHMP, the Committee of the European Medicines Agency, has granted a positive opinion for VENCLYXTO (venetoclax) in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia who were previously untreated. VENCLYXTO is being developed by AbbVie and Roche.... |
24,730 | 2020-01-31 00:00:00 UTC | Eli Lilly Launches a New Migraine Drug | ABBV | https://www.nasdaq.com/articles/eli-lilly-launches-a-new-migraine-drug-2020-01-31-0 | null | null | Eli Lilly (NYSE: LLY) launched its new pill for the acute treatment of migraines Friday after the Drug Enforcement Administration completed its review of the drug and classified it as having a low potential for abuse or dependence. Reyvow is the first drug of a new class, and treats not only pain, but sensitivity to l... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Reyvow was approved by th... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Eli Lilly (NYSE: LLY) lau... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Eli Lilly (NYSE: LLY) lau... | Allergan (NYSE: AGN), which is seeking to merge with AbbVie (NYSE: ABBV), received approval in December for Ugality, an oral acute treatment of migraines that's in the same drug class as Emgality. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly owns shares of AbbVie. Eli Lilly (NYSE: LLY) lau... |
24,731 | 2020-01-30 00:00:00 UTC | Relative Strength Alert For AbbVie | ABBV | https://www.nasdaq.com/articles/relative-strength-alert-for-abbvie-2020-01-30 | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.2, after changing hands as low as $81.18 per share. A bullish investor could look at ABBV's 28.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and... | A bullish investor could look at ABBV's 28.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in i... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.2, after changing hands as low as $81.18 per share. A bullish investor could look at ABBV's 28.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.2, after changing hands as low as $81.18 per share. A bullish investor could look at ABBV's 28.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and... |
24,732 | 2020-01-30 00:00:00 UTC | March 13th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/march-13th-options-now-available-for-abbvie-abbv-2020-01-30 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the March 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 13th contracts and identified one put and one call contract of particular interest.
The put contract... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $82.00 strike highlighted in red: Considering the fact that the $82.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $78.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $82.00 strike price has a current bid of 50 cents. Below is a chart showing AB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 13th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $82.00 strike highlighted in red: Consideri... |
24,733 | 2020-01-29 00:00:00 UTC | IWM, RNDV: Big ETF Outflows | ABBV | https://www.nasdaq.com/articles/iwm-rndv%3A-big-etf-outflows-2020-01-29 | null | null | Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares Russell 2000 ETF, where 7,250,000 units were destroyed, or a 2.6% decrease week over week. Among the largest underlying components of IWM, in morning trading today Novocure ... | Among the largest underlying components of RNDV, in morning trading today Intelsat is down about 21.9%, and Abbvie is lower by about 0.3%. Among the largest underlying components of IWM, in morning trading today Novocure is up about 0.1%, and Teladoc Health is higher by about 1.2%. And on a percentage change basis, the... | Among the largest underlying components of RNDV, in morning trading today Intelsat is down about 21.9%, and Abbvie is lower by about 0.3%. Among the largest underlying components of IWM, in morning trading today Novocure is up about 0.1%, and Teladoc Health is higher by about 1.2%. VIDEO: IWM, RNDV: Big ETF Outflows Th... | Among the largest underlying components of RNDV, in morning trading today Intelsat is down about 21.9%, and Abbvie is lower by about 0.3%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares Russell 2000 ETF, where 7,250,000 ... | Among the largest underlying components of RNDV, in morning trading today Intelsat is down about 21.9%, and Abbvie is lower by about 0.3%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares Russell 2000 ETF, where 7,250,000 ... |
24,734 | 2020-01-29 00:00:00 UTC | 2 of the Best Healthcare Stocks to Buy Today | ABBV | https://www.nasdaq.com/articles/2-of-the-best-healthcare-stocks-to-buy-today-2020-01-29 | null | null | The healthcare industry is a great place to invest because it can give investors some safe stocks to buy and hold. Health stocks are normally not very volatile and they can be profitable investments to put in your portfolio for many years.
One criticism is that they may lack growth opportunities. However, that's not th... | But there's reason to be positive: Despite all the noise and acquisitions, AbbVie has found a way to make it all work, consistently reporting net income of more than $5 billion in each of the past three years. AbbVie AbbVie (NYSE: ABBV) is another stock that's been showing nice growth of late, with sales up 16% in 2018... | AbbVie AbbVie (NYSE: ABBV) is another stock that's been showing nice growth of late, with sales up 16% in 2018 and 10% the year before that. That growth has largely come through acquisitions, which AbbVie doesn't always have a great track record with. But there's reason to be positive: Despite all the noise and acquisi... | AbbVie AbbVie (NYSE: ABBV) is another stock that's been showing nice growth of late, with sales up 16% in 2018 and 10% the year before that. Good healthcare stocks to build your portfolio around These stocks have struggled in recent years, with AbbVie falling 26% in two years and Biogen falling 17%, while the Health Ca... | That growth has largely come through acquisitions, which AbbVie doesn't always have a great track record with. AbbVie AbbVie (NYSE: ABBV) is another stock that's been showing nice growth of late, with sales up 16% in 2018 and 10% the year before that. But there's reason to be positive: Despite all the noise and acquisi... |
24,735 | 2020-01-28 00:00:00 UTC | 3 Dividend Stocks Perfect for Retirees | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-perfect-for-retirees-2020-01-28 | null | null | A well-constructed dividend portfolio can help pave the way to greater financial flexibility in retirement and help you enjoy your later years in style. Many retirees rely on dividend-paying stocks for extra income, but not every stock that offers a substantial yield will wind up pulling its weight in a retirement port... | AbbVie 5.7% 47 years 195% 54.3% *Payout growth streak includes AbbVie's time as part of Abbott Laboratories. Sources: AbbVie, Yahoo! | 5.7% 47 years 195% 54.3% *Payout growth streak includes AbbVie's time as part of Abbott Laboratories. AbbVie Sources: AbbVie, Yahoo! | AbbVie 5.7% 47 years 195% 54.3% *Payout growth streak includes AbbVie's time as part of Abbott Laboratories. Sources: AbbVie, Yahoo! | While the market balked at the price of the Allergan acquisition, the deal will significantly boost AbbVie's cash flow and put it in even better position to continue delivering substantial payout growth over the next decade and beyond. AbbVie 5.7% 47 years 195% 54.3% *Payout growth streak includes AbbVie's time as part... |
24,736 | 2020-01-27 00:00:00 UTC | AbbVie's Acquisition of Allergan Gets Help From Nestle and AstraZeneca | ABBV | https://www.nasdaq.com/articles/abbvies-acquisition-of-allergan-gets-help-from-nestle-and-astrazeneca-2020-01-27 | null | null | Some unlikely good Samaritans are going out of their way to help AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. To appease antitrust regulators, AstraZeneca (NYSE: AZN) will take back control of an experimental psoriasis drug, and Nestle will ... | Some unlikely good Samaritans are going out of their way to help AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. AbbVie recently launched its own IL-23 inhibitor, risankizumab, under the brand name Skyrizi for the treatment of psoriasis. To app... | Some unlikely good Samaritans are going out of their way to help AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. AbbVie recently launched its own IL-23 inhibitor, risankizumab, under the brand name Skyrizi for the treatment of psoriasis. Hello ... | Some unlikely good Samaritans are going out of their way to help AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. AbbVie recently launched its own IL-23 inhibitor, risankizumab, under the brand name Skyrizi for the treatment of psoriasis. To app... | Some unlikely good Samaritans are going out of their way to help AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. AbbVie recently launched its own IL-23 inhibitor, risankizumab, under the brand name Skyrizi for the treatment of psoriasis. Nestle... |
24,737 | 2020-01-27 00:00:00 UTC | Allergan To Sell Brazikumab To AstraZeneca, Zenpep To Nestle Under AbbVie Merger | ABBV | https://www.nasdaq.com/articles/allergan-to-sell-brazikumab-to-astrazeneca-zenpep-to-nestle-under-abbvie-merger-2020-01-27 | null | null | (RTTNews) - Allergan plc (AGN), which is in deal to be bought by AbbVie (ABBV), announced Monday that it has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase) to AstraZeneca (AZN, AZN.L) and Nestle SA (NSRGY.PK, NSTR.L), respectively.
The companies did not disclose the ... | (RTTNews) - Allergan plc (AGN), which is in deal to be bought by AbbVie (ABBV), announced Monday that it has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase) to AstraZeneca (AZN, AZN.L) and Nestle SA (NSRGY.PK, NSTR.L), respectively. The agreements are in conjunction w... | The closings of the acquisitions of brazikumab and Zenpep are contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, closing of AbbVie's pending acquisition of Allergan and the satisfaction of other customary closing conditions. On January 10, AbbVie and Allergan received conditional... | (RTTNews) - Allergan plc (AGN), which is in deal to be bought by AbbVie (ABBV), announced Monday that it has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase) to AstraZeneca (AZN, AZN.L) and Nestle SA (NSRGY.PK, NSTR.L), respectively. The closings of the acquisitions of... | The closings of the acquisitions of brazikumab and Zenpep are contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, closing of AbbVie's pending acquisition of Allergan and the satisfaction of other customary closing conditions. AbbVie and Allergan continue to expect to close the dea... |
24,738 | 2020-01-24 00:00:00 UTC | Fitch Ratings Says Impeachment Trial Won't Hurt Healthcare Investment in 2020 | ABBV | https://www.nasdaq.com/articles/fitch-ratings-says-impeachment-trial-wont-hurt-healthcare-investment-in-2020-2020-01-25 | null | null | Healthcare markets in the U.S. have a lot to be anxious about in 2020, with federal elections looming while the impeachment trial of President Trump continues to develop. In spite of this, however, top credit agency Fitch Ratings predicts that U.S. healthcare investment will remain strong.
Although healthcare megamerge... | AbbVie's (NYSE: ABBV) whopping $63 billion deal with Allergan, CVS Health's (NYSE: CVS) $69 billion acquisition of Aetna, and Bristol-Myers' (NYSE: BMY) even larger $74 billion deal with Celgene are three of the largest deals made last year. Healthcare markets in the U.S. have a lot to be anxious about in 2020, with fe... | AbbVie's (NYSE: ABBV) whopping $63 billion deal with Allergan, CVS Health's (NYSE: CVS) $69 billion acquisition of Aetna, and Bristol-Myers' (NYSE: BMY) even larger $74 billion deal with Celgene are three of the largest deals made last year. In spite of this, however, top credit agency Fitch Ratings predicts that U.S. ... | AbbVie's (NYSE: ABBV) whopping $63 billion deal with Allergan, CVS Health's (NYSE: CVS) $69 billion acquisition of Aetna, and Bristol-Myers' (NYSE: BMY) even larger $74 billion deal with Celgene are three of the largest deals made last year. A strong year for healthcare mergers The past year has seen a number of signif... | AbbVie's (NYSE: ABBV) whopping $63 billion deal with Allergan, CVS Health's (NYSE: CVS) $69 billion acquisition of Aetna, and Bristol-Myers' (NYSE: BMY) even larger $74 billion deal with Celgene are three of the largest deals made last year. In spite of this, however, top credit agency Fitch Ratings predicts that U.S. ... |
24,739 | 2020-01-24 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-johnson-johnson-2020-01-24 | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two of the largest pharmaceutical companies in the world. However, big doesn't mean buy, and both of these juggernauts currently face headwinds that may scare many investors away. AbbVie is dealing with Humira's declining international sales caused by competitio... | By contrast, AbbVie's acquisition of Allergan has yet to close, and there's still some uncertainty as to how this move will affect the company's financial performance in the future. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two of the largest pharmaceutical companies in the world. AbbVie is dealing with... | Profitability and valuation During the third quarter, AbbVie posted net earnings of $1.9 billion, a 31.4% decrease year over year; the company also recorded an earnings per share (EPS) of $1.26, down from $1.81 compared to the year-ago period. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two of the largest... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two of the largest pharmaceutical companies in the world. AbbVie is dealing with Humira's declining international sales caused by competition from biosimilars in Europe. The case for AbbVie Despite Humira's declining prospects in Europe, the drug is still rackin... | The case for AbbVie Despite Humira's declining prospects in Europe, the drug is still racking up strong -- and growing -- sales in the U.S. During the third quarter, U.S. sales of Humira were $3.9 billion, a 9.6% increase year over year. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two of the largest pharm... |
24,740 | 2020-01-23 00:00:00 UTC | Notable Thursday Option Activity: ABBV, EBAY, MED | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-abbv-ebay-med-2020-01-23 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 30,912 contracts has been traded thus far today, a contract volume which is representative of approximately 3.1 million underlying shares (given that e... | Particularly high volume was seen for the $100 strike call option expiring January 15, 2021, with 2,262 contracts trading so far today, representing approximately 226,200 underlying shares of ABBV. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbV... | Particularly high volume was seen for the $100 strike call option expiring January 15, 2021, with 2,262 contracts trading so far today, representing approximately 226,200 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: eBay In... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 30,912 contracts has been traded thus far today, a contract volume which is representative of approximately 3.1 million underlying shares (given that e... | Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: eBay Inc. (Symbol: EBAY) saw options trading volume of 29,818 contracts, representing approximately 3.0 million underlying shares or approximately 43.7% of EBAY's average daily trading volume over the past... |
24,741 | 2020-01-23 00:00:00 UTC | 2 Dividend-Paying Biotech Stocks Worth Owning in 2020 | ABBV | https://www.nasdaq.com/articles/2-dividend-paying-biotech-stocks-worth-owning-in-2020-2020-01-23 | null | null | Dividend stocks are a powerful way to boost the return on capital of any portfolio. That being said, it can be a chore to unearth income stocks worth owning for long periods of time. The fundamental problem is that most companies simply can't maintain their status as a top dog for lengthy periods of time. Moreover, the... | In all, AbbVie's bottom of the barrel valuation, junk-bond-like dividend yield, and strong track record as a top growth play make this stock an outstanding buy this year. The blue-chip biotechs AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are unique in this regard. Nonetheless, the moody market has still seen... | At current levels, AbbVie's stock is paying a forward-looking yield of 5.36%. The blue-chip biotechs AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are unique in this regard. Nonetheless, the moody market has still seen fit to reward AbbVie and Gilead with clearance-rack valuations. | AbbVie, for instance, is presently trading at a rock-bottom 9.19 times forward-looking earnings, and Gilead's stock is even cheaper at 9.09 times next year's projected earnings. Gilead: Safety, innovation, and financial firepower all in one package Like AbbVie, Gilead hasn't exactly been a popular name among investors ... | The blue-chip biotechs AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are unique in this regard. Nonetheless, the moody market has still seen fit to reward AbbVie and Gilead with clearance-rack valuations. AbbVie, for instance, is presently trading at a rock-bottom 9.19 times forward-looking earnings, and Gilea... |
24,742 | 2020-01-21 00:00:00 UTC | Buffett Owns Teva Stock, But Should You? | ABBV | https://www.nasdaq.com/articles/buffett-owns-teva-stock-but-should-you-2020-01-21 | null | null | What a tough ride it has been for Teva Pharmaceutical (NYSE:). Four years ago â which feels like a lifetime in the stock market â Teva stock was a $60-plus stock. Now? After a 16% rally last week, the stock is finally back over ⦠$10.
Source: JHVEPhoto / Shutterstock.com
Yeah, thatâÂÂs the kind of rid... | And while many healthcare stocks have big balance sheets due to mergers and acquisitions â such as Bristol-Myers Squibb (NYSE:) buying Celgene or AbbVie (NYSE:) buying Allergan (NYSE:) â Teva just canâÂÂt get out of its own way. Proper risk management could have prevented a bulk of the losses, and should s... | And while many healthcare stocks have big balance sheets due to mergers and acquisitions â such as Bristol-Myers Squibb (NYSE:) buying Celgene or AbbVie (NYSE:) buying Allergan (NYSE:) â Teva just canâÂÂt get out of its own way. Trading Teva Stock Source: Chart courtesy of There are obviously some flaws wh... | And while many healthcare stocks have big balance sheets due to mergers and acquisitions â such as Bristol-Myers Squibb (NYSE:) buying Celgene or AbbVie (NYSE:) buying Allergan (NYSE:) â Teva just canâÂÂt get out of its own way. Four years ago â which feels like a lifetime in the stock market â T... | And while many healthcare stocks have big balance sheets due to mergers and acquisitions â such as Bristol-Myers Squibb (NYSE:) buying Celgene or AbbVie (NYSE:) buying Allergan (NYSE:) â Teva just canâÂÂt get out of its own way. Four years ago â which feels like a lifetime in the stock market â T... |
24,743 | 2020-01-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 1/19/2020 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-1-19-2020-2020-01-19 | null | null | The following are the top rated Healthcare stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Biotechnology ... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea'... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of June 30, 2016, the Pharmaceutical Distribution segment consists o... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Dymatize brand's portfolio includes an assortment of sports nutrition p... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea'... |
24,744 | 2020-01-19 00:00:00 UTC | 2 Biotechs Battling Immune Diseases | ABBV | https://www.nasdaq.com/articles/2-biotechs-battling-immune-diseases-2020-01-19 | null | null | On some levels, Rigel Pharmaceuticals (NASDAQ: RIGL) and Momenta Pharmaceuticals (NASDAQ: MNTA) are complete opposites. Rigel, based in South San Francisco, focuses on small molecule drugs while Momenta, headquartered in Cambridge, Massachusetts, tackles disease using large molecules called biologics.
Rigel, with a dru... | Tavalisse, Rigel's approved drug, was returned to Rigel from AstraZeneca following a phase 2b clinical trial that did not show superiority to AbbVie's Humira. Rigel has two oral treatments in early human testing in addition to several early-stage programs in oncology, dermatology, and asthma where the research is being... | Tavalisse, Rigel's approved drug, was returned to Rigel from AstraZeneca following a phase 2b clinical trial that did not show superiority to AbbVie's Humira. Rigel spent its early years developing several drugs that didn't pan out, including an asthma drug that both Pfizer and AstraZeneca took turns developing before ... | Tavalisse, Rigel's approved drug, was returned to Rigel from AstraZeneca following a phase 2b clinical trial that did not show superiority to AbbVie's Humira. Rigel, with a drug approved in the U.S. and Europe, sports a market cap of roughly $475 million compared to Momenta's $2.6 billion valuation. Rigel spent its ear... | Tavalisse, Rigel's approved drug, was returned to Rigel from AstraZeneca following a phase 2b clinical trial that did not show superiority to AbbVie's Humira. On some levels, Rigel Pharmaceuticals (NASDAQ: RIGL) and Momenta Pharmaceuticals (NASDAQ: MNTA) are complete opposites. Rigel markets the oral drug Tavalisse for... |
24,745 | 2020-01-18 00:00:00 UTC | Where Will Abbott Laboratories Be in 5 Years? | ABBV | https://www.nasdaq.com/articles/where-will-abbott-laboratories-be-in-5-years-2020-01-18 | null | null | Abbott Laboratories (NYSE: ABT) has been one of the better performing large-cap healthcare stocks on the market, although many years ago the company was going through a major change. Back in 2013, Abbott's drug business ended up splitting off from the firm to form a separate company called AbbVie. In this split, AbbVie... | Back in 2013, Abbott's drug business ended up splitting off from the firm to form a separate company called AbbVie. In this split, AbbVie maintained ownership of a number of blockbuster drugs, the most notable being Humira. Abbott Laboratories (NYSE: ABT) has been one of the better performing large-cap healthcare stock... | Back in 2013, Abbott's drug business ended up splitting off from the firm to form a separate company called AbbVie. In this split, AbbVie maintained ownership of a number of blockbuster drugs, the most notable being Humira. The best single business segment for Abbott has been its international medical device business, ... | Back in 2013, Abbott's drug business ended up splitting off from the firm to form a separate company called AbbVie. In this split, AbbVie maintained ownership of a number of blockbuster drugs, the most notable being Humira. What's particularly impressive is that the annual growth rate of Abbott's medical device busines... | Back in 2013, Abbott's drug business ended up splitting off from the firm to form a separate company called AbbVie. In this split, AbbVie maintained ownership of a number of blockbuster drugs, the most notable being Humira. Despite the loss of these blockbuster drugs and their impressive revenue figures, Abbott has gro... |
24,746 | 2020-01-16 00:00:00 UTC | Why AbbVie Stock Dipped in 2019 | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-dipped-in-2019-2020-01-16 | null | null | What happened
Shares of pharma giant AbbVie (NYSE: ABBV) dipped by 3.96% over the course of 2019, according to data from S&P Global Market Intelligence. The drugmaker's stock slipped last year for two fundamental reasons:
International sales of AbbVie's flagship arthritis medicine, Humira, dropped markedly in 2019 due ... | The drugmaker's stock slipped last year for two fundamental reasons: International sales of AbbVie's flagship arthritis medicine, Humira, dropped markedly in 2019 due to the launch of biosimilars in key territories. AbbVie's decision to offset Humira's fading star by merging with Botox maker Allergan (NYSE: AGN) later ... | What happened Shares of pharma giant AbbVie (NYSE: ABBV) dipped by 3.96% over the course of 2019, according to data from S&P Global Market Intelligence. The drugmaker's stock slipped last year for two fundamental reasons: International sales of AbbVie's flagship arthritis medicine, Humira, dropped markedly in 2019 due ... | The drugmaker's stock slipped last year for two fundamental reasons: International sales of AbbVie's flagship arthritis medicine, Humira, dropped markedly in 2019 due to the launch of biosimilars in key territories. What happened Shares of pharma giant AbbVie (NYSE: ABBV) dipped by 3.96% over the course of 2019, accord... | What happened Shares of pharma giant AbbVie (NYSE: ABBV) dipped by 3.96% over the course of 2019, according to data from S&P Global Market Intelligence. The drugmaker's stock slipped last year for two fundamental reasons: International sales of AbbVie's flagship arthritis medicine, Humira, dropped markedly in 2019 due ... |
24,747 | 2020-01-16 00:00:00 UTC | Beyond the Growing Dividend, Abbvie Stock Is a Good Buy Here | ABBV | https://www.nasdaq.com/articles/beyond-the-growing-dividend-abbvie-stock-is-a-good-buy-here-2020-01-16 | null | null | Abbvie (NYSE:) is up over 40% since its mid-August 2019 lows, but amazingly Abbvie stock still offers great value to investors.
Source: Piotr Swat / Shutterstock.com
For example, ABBV has a of 4.8% and a prospective price-to-earnings ratio of just 9 times. This is significantly below the averages for the S&P 500.
I hav... | For example, the chart below shows that Abbvie has regularly raised its dividend per share in the past five years. Abbvie says the deal gives it âÂÂnew growth platformsâ and is âÂÂtransformative.â The combined company generated $19 billion in operating cash flow in 2018. Abbvie (NYSE:) is up over 40% si... | The dividend is expected to rise by 10% this year Source: Mark R. Hake Moreover, Abbvie is close to closing on its mid-June 2019 acquisition ofàAllergan (NYSE:).àAllergan is well known for its Botox and other beauty products. Valuing Abbvie Stock Assuming the deal closes and everything works out, Abbvie should ... | The dividend is expected to rise by 10% this year Source: Mark R. Hake Moreover, Abbvie is close to closing on its mid-June 2019 acquisition ofàAllergan (NYSE:).àAllergan is well known for its Botox and other beauty products. Valuing Abbvie Stock Assuming the deal closes and everything works out, Abbvie should ... | The dividend is expected to rise by 10% this year Source: Mark R. Hake Moreover, Abbvie is close to closing on its mid-June 2019 acquisition ofàAllergan (NYSE:).àAllergan is well known for its Botox and other beauty products. Abbvie (NYSE:) is up over 40% since its mid-August 2019 lows, but amazingly Abbvie sto... |
24,748 | 2020-01-16 00:00:00 UTC | 5 Key Things Investors Should Look Forward to With AbbVie in 2020 | ABBV | https://www.nasdaq.com/articles/5-key-things-investors-should-look-forward-to-with-abbvie-in-2020-2020-01-16 | null | null | AbbVie (NYSE: ABBV) shareholders didn't have a lot to get excited about last year. The stock finished 2019 down 4%, while the S&P 500 surged 29%. But the big drugmaker's future is a lot more important than its past.
Rick Gonzalez, AbbVie's CEO, along with a couple of other top executives had an opportunity to talk abo... | AbbVie recently announced plans to set up Allergan's medical-aesthetics business as a stand-alone unit with its own research and development team. Earlier this week, AbbVie announced encouraging results from a late-stage study evaluating Skyrizi in a head-to-head matchup with Novartis' Cosentyx. AbbVie (NYSE: ABBV) sha... | Lots of pipeline updates AbbVie president Mike Severino provided an update on the company's pipeline programs. AbbVie (NYSE: ABBV) shareholders didn't have a lot to get excited about last year. Rick Gonzalez, AbbVie's CEO, along with a couple of other top executives had an opportunity to talk about AbbVie's future on W... | Rick Gonzalez, AbbVie's CEO, along with a couple of other top executives had an opportunity to talk about AbbVie's future on Wednesday at the J.P. Morgan Healthcare Conference in San Francisco. 5. Dividend growth (but at a slower pace) AbbVie ranks as one of the most attractive dividend stocks on the market right now. ... | AbbVie (NYSE: ABBV) shareholders didn't have a lot to get excited about last year. Rick Gonzalez, AbbVie's CEO, along with a couple of other top executives had an opportunity to talk about AbbVie's future on Wednesday at the J.P. Morgan Healthcare Conference in San Francisco. Here are five key things that investors sho... |
24,749 | 2020-01-16 00:00:00 UTC | The Best Large-Cap ETFs to Buy in 2020 | ABBV | https://www.nasdaq.com/articles/the-best-large-cap-etfs-to-buy-in-2020-2020-01-16 | null | null | If you're just beginning to learn how to invest in stocks, it can be wise to start building your portfolio around exchange-traded funds (ETFs), which offer an easy passive path to diversified holdings. To be clear, ETFs aim to essentially track the market, rather than beat it.
My preference when it comes to ETFs is to... | Top names include AbbVie, AT&T, IBM, and ExxonMobil. If you're just beginning to learn how to invest in stocks, it can be wise to start building your portfolio around exchange-traded funds (ETFs), which offer an easy passive path to diversified holdings. The funds top 10 holdings include names like Apple, Microsoft, an... | Top names include AbbVie, AT&T, IBM, and ExxonMobil. Schwab US Large-Cap Growth ETF The Schwab US Large-Cap Growth ETF (NYSEMKT: SCHG) offers domestic exposure to some of the best growth companies. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Apple, Berkshire Hathaway ... | Top names include AbbVie, AT&T, IBM, and ExxonMobil. Image Source: Getty Images SPDR S&P Dividend ETF With an annualized rate of return of 9.29%, the SPDR S&P Dividend ETF (NYSEMKT: SDY) obviously underperforms the market, but for the low-risk type of fund it is, it offers a good risk-reward scenario. Investing in equi... | Top names include AbbVie, AT&T, IBM, and ExxonMobil. The funds top 10 holdings include names like Apple, Microsoft, and Amazon, while also carrying exposure to the investment prowess of Berkshire Hathaway, as well as steady stocks like Visa and Mastercard. Offering a dividend that currently yields 2.46%, and with a thr... |
24,750 | 2020-01-15 00:00:00 UTC | High Drug Prices Remains a Top Issue in Democratic Debates | ABBV | https://www.nasdaq.com/articles/high-drug-prices-remains-a-top-issue-in-democratic-debates-2020-01-15 | null | null | One of the top issues discussed at Tuesday's Democratic debate in Iowa was healthcare. Specifically, how to lower drug prices which have been ballooning over the past few years.
Sen. Elizabeth Warren has promised to use executive action to make it easier for generic drug manufacturers to compete with branded drugs, esp... | This included the chief executives from AbbVie, AstraZeneca, and six other top pharmaceutical companies. While drug costs have always been a major issue for Democrats, healthcare questions in previous debates have revolved more around improving Medicare access. A recent press release issued by the Trump administration ... | This included the chief executives from AbbVie, AstraZeneca, and six other top pharmaceutical companies. Sen. Bernie Sanders, has also made comments regarding the nature of major pharmaceutical companies, singling out firms that charge more in the U.S. than in other nations. After all, the newsletter they have run for ... | This included the chief executives from AbbVie, AstraZeneca, and six other top pharmaceutical companies. Sen. Elizabeth Warren has promised to use executive action to make it easier for generic drug manufacturers to compete with branded drugs, especially if they received funding from federal sources. While drug costs h... | This included the chief executives from AbbVie, AstraZeneca, and six other top pharmaceutical companies. While drug costs have always been a major issue for Democrats, healthcare questions in previous debates have revolved more around improving Medicare access. 10 stocks we like better than AstraZeneca When investing g... |
24,751 | 2020-01-14 00:00:00 UTC | Notable Tuesday Option Activity: COF, ABBV, HBI | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-cof-abbv-hbi-2020-01-14 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Capital One Financial Corp (Symbol: COF), where a total volume of 25,170 contracts has been traded thus far today, a contract volume which is representative of approximately 2.5 million underlying shares (gi... | Particularly high volume was seen for the $77.50 strike call option expiring January 17, 2020, with 39,263 contracts trading so far today, representing approximately 3.9 million underlying shares of ABBV. Below is a chart showing COF's trailing twelve month trading history, with the $103 strike highlighted in orange: A... | Below is a chart showing COF's trailing twelve month trading history, with the $103 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 99,605 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $77.50 strike highlighted in orange... | Below is a chart showing ABBV's trailing twelve month trading history, with the $77.50 strike highlighted in orange: And HanesBrands Inc (Symbol: HBI) saw options trading volume of 61,777 contracts, representing approximately 6.2 million underlying shares or approximately 107.3% of HBI's average daily trading volume ov... | Particularly high volume was seen for the $77.50 strike call option expiring January 17, 2020, with 39,263 contracts trading so far today, representing approximately 3.9 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $77.50 strike highlighted in orange... |
24,752 | 2020-01-14 00:00:00 UTC | AbbVie : Late-stage Plaque Psoriasis Study Meets Primary & Secondary Endpoints | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-late-stage-plaque-psoriasis-study-meets-primary-secondary-endpoints-2020-01-14 | null | null | (RTTNews) - AbbVie (ABBV) said that new head-to-head phase 3 data show skyrizi superior to cosentyx across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks.
Of patients treated with skyrizi, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated p... | (RTTNews) - AbbVie (ABBV) said that new head-to-head phase 3 data show skyrizi superior to cosentyx across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading developmen... | (RTTNews) - AbbVie (ABBV) said that new head-to-head phase 3 data show skyrizi superior to cosentyx across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading developmen... | (RTTNews) - AbbVie (ABBV) said that new head-to-head phase 3 data show skyrizi superior to cosentyx across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading developmen... | (RTTNews) - AbbVie (ABBV) said that new head-to-head phase 3 data show skyrizi superior to cosentyx across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading developmen... |
24,753 | 2020-01-13 00:00:00 UTC | 2020 J.P. Morgan Healthcare Conference Roundup | ABBV | https://www.nasdaq.com/articles/2020-j.p.-morgan-healthcare-conference-roundup-2020-01-13 | null | null | The 38th annual J.P. Morgan (NYSE: JPM) Healthcare Conference kicks off on Monday, Jan. 13, 2020 in San Francisco and healthcare investors are closely listening to presentations by executives leading the world's most powerful drug and biotech companies.
More than 450 companies will be presenting, including AbbVie (NYSE... | More than 450 companies will be presenting, including AbbVie (NYSE: ABBV), Amarin (NASDAQ: AMRN), and Bristol-Myers Squibb (NYSE: BMY) to more than 9,000 attendees. The Motley Fool's healthcare team will keep you informed about the most important announcements and offer our expert analysis. Image Source: Getty Images A... | More than 450 companies will be presenting, including AbbVie (NYSE: ABBV), Amarin (NASDAQ: AMRN), and Bristol-Myers Squibb (NYSE: BMY) to more than 9,000 attendees. The Motley Fool's healthcare team will keep you informed about the most important announcements and offer our expert analysis. After all, the newsletter th... | More than 450 companies will be presenting, including AbbVie (NYSE: ABBV), Amarin (NASDAQ: AMRN), and Bristol-Myers Squibb (NYSE: BMY) to more than 9,000 attendees. Image Source: Getty Images All the 2020 Pre-JPM News Healthcare Investors Need to Know 3 Top Biotech Stocks to Buy in January 3 Things We Might Hear From I... | More than 450 companies will be presenting, including AbbVie (NYSE: ABBV), Amarin (NASDAQ: AMRN), and Bristol-Myers Squibb (NYSE: BMY) to more than 9,000 attendees. That's right -- they think these 10 stocks are even better buys. The Motley Fool has a disclosure policy. |
24,754 | 2020-01-13 00:00:00 UTC | 7 Great High-Yield Stocks With Payouts Over 5% | ABBV | https://www.nasdaq.com/articles/7-great-high-yield-stocks-with-payouts-over-5-2020-01-13 | null | null | EditorâÂÂs note: This story was previouslyàpublished in November 2019. It has since been updated and republished.
ItâÂÂs not as easy as it looks to pick high-yield dividend stocks because theyâÂÂre often yielding more than 5% for a reason. Something about the company or industry has broken down, pushing th... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, youâÂÂre looking like a regular genius right about now. Up 42% from its 52-week low of $62.66, ABBV stock is still yielding an attractive 5.27%.àHow did AbbVie drop so far after starting 2019 around $90? In ad... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, youâÂÂre looking like a regular genius right about now. Up 42% from its 52-week low of $62.66, ABBV stock is still yielding an attractive 5.27%.àHow did AbbVie drop so far after starting 2019 around $90? In ad... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, youâÂÂre looking like a regular genius right about now. Up 42% from its 52-week low of $62.66, ABBV stock is still yielding an attractive 5.27%.àHow did AbbVie drop so far after starting 2019 around $90? In ad... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com If you happened to buy AbbVie (NYSE:) in mid-August, youâÂÂre looking like a regular genius right about now. Up 42% from its 52-week low of $62.66, ABBV stock is still yielding an attractive 5.27%.àHow did AbbVie drop so far after starting 2019 around $90? In ad... |
24,755 | 2020-01-13 00:00:00 UTC | Why AbbVie Could Be a Great Buy in 2020 | ABBV | https://www.nasdaq.com/articles/why-abbvie-could-be-a-great-buy-in-2020-2020-01-13 | null | null | AbbVie (NYSE: ABBV) could be poised for a great year. The company will close its acquisition of drug manufacturer Allergan (NYSE: AGN) early this year, which will help pad AbbVie's results, add more products into its portfolio, and diversify its revenue stream by adding more brands.
There's one drug in particular that ... | The company will close its acquisition of drug manufacturer Allergan (NYSE: AGN) early this year, which will help pad AbbVie's results, add more products into its portfolio, and diversify its revenue stream by adding more brands. Strong contributions from Allergan could help AbbVie's stock soar Any time there's a big a... | The company will close its acquisition of drug manufacturer Allergan (NYSE: AGN) early this year, which will help pad AbbVie's results, add more products into its portfolio, and diversify its revenue stream by adding more brands. With AbbVie's acquisition of Allergan expected to close early this year and the potential ... | The company will close its acquisition of drug manufacturer Allergan (NYSE: AGN) early this year, which will help pad AbbVie's results, add more products into its portfolio, and diversify its revenue stream by adding more brands. With AbbVie's acquisition of Allergan expected to close early this year and the potential ... | With AbbVie's acquisition of Allergan expected to close early this year and the potential benefits of Ubrelvy sales, 2020 could be a good year for the healthcare stock, and its top and bottom lines could come in better than expected. AbbVie (NYSE: ABBV) could be poised for a great year. The company will close its acqui... |
24,756 | 2020-01-12 00:00:00 UTC | 3 High-Yield Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-id-buy-right-now-2020-01-12 | null | null | There are plenty of high-yield dividend stocks that I wouldn't touch with a 10-foot pole. Their business models are shaky. The dividend is in jeopardy of being slashed. Many high-yield dividend stocks simply aren't good picks for long-term investors.
But there are also quite a few stocks with high dividend yields that ... | Three such stocks that I'd buy right now are AbbVie (NYSE: ABBV), Brookfield Infrastructure Partners (NYSE: BIP), and Innovative Industrial Partners (NYSE: IIPR). AbbVie AbbVie's dividend currently yields a mouthwatering 5.3%. However, I think that AbbVie has a pretty good strategy to handle Humira's inevitable decline... | Three such stocks that I'd buy right now are AbbVie (NYSE: ABBV), Brookfield Infrastructure Partners (NYSE: BIP), and Innovative Industrial Partners (NYSE: IIPR). AbbVie AbbVie's dividend currently yields a mouthwatering 5.3%. However, I think that AbbVie has a pretty good strategy to handle Humira's inevitable decline... | Three such stocks that I'd buy right now are AbbVie (NYSE: ABBV), Brookfield Infrastructure Partners (NYSE: BIP), and Innovative Industrial Partners (NYSE: IIPR). Although the company doesn't have the long history of dividend hikes that AbbVie does, it has boosted its dividend by 42% over the last five years, which isn... | AbbVie AbbVie's dividend currently yields a mouthwatering 5.3%. Although the company doesn't have the long history of dividend hikes that AbbVie does, it has boosted its dividend by 42% over the last five years, which isn't shabby at all. Three such stocks that I'd buy right now are AbbVie (NYSE: ABBV), Brookfield Infr... |
24,757 | 2020-01-10 00:00:00 UTC | 7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount | ABBV | https://www.nasdaq.com/articles/7-healthcare-stocks-to-buy-or-sell-as-pricing-pressures-mount-2020-01-10 | null | null | There has been a great deal of discussion about how drug prices will change in coming years. The fact that this is an election year surely sticks in tradersâ minds. If you remember back to the 2016 election cycle, biotech shares went into a brutal downturn after Hillary Clinton castigated the pharma industry for i... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NASDAQ:) is the pharma spin-off from healthcare and medical devices leader Abbott (NYSE:). Abbott seems to have made a wise move in spinning off AbbVie. Since the companies parted ways, AbbottâÂÂs stock has more than doubled, while AbbVie has had a more dif... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NASDAQ:) is the pharma spin-off from healthcare and medical devices leader Abbott (NYSE:). Abbott seems to have made a wise move in spinning off AbbVie. Since the companies parted ways, AbbottâÂÂs stock has more than doubled, while AbbVie has had a more dif... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NASDAQ:) is the pharma spin-off from healthcare and medical devices leader Abbott (NYSE:). Abbott seems to have made a wise move in spinning off AbbVie. Since the companies parted ways, AbbottâÂÂs stock has more than doubled, while AbbVie has had a more dif... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NASDAQ:) is the pharma spin-off from healthcare and medical devices leader Abbott (NYSE:). Abbott seems to have made a wise move in spinning off AbbVie. Since the companies parted ways, AbbottâÂÂs stock has more than doubled, while AbbVie has had a more dif... |
24,758 | 2020-01-10 00:00:00 UTC | Noteworthy ETF Outflows: IWF, ABBV, COST, NKE | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-iwf-abbv-cost-nke-2020-01-10 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $235.0 million dollar outflow -- that's a 0.5% decrease week over week (from 281,050,000 to 279,750,000). ... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Costco Wholesale Corp (Symbol: COST) is off about 0.3%, and Nike (Symbol: NKE) is lower by about 0.1%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Costco Wholesale Corp (Symbol: COST) is off about 0.3%, and Nike (Symbol: NKE) is lower by about 0.1%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Costco Wholesale Corp (Symbol: COST) is off about 0.3%, and Nike (Symbol: NKE) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Costco Wholesale Corp (Symbol: COST) is off about 0.3%, and Nike (Symbol: NKE) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... |
24,759 | 2020-01-08 00:00:00 UTC | Insiders Buy the Holdings of DHS ETF | ABBV | https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-dhs-etf-2020-01-08 | null | null | A look at the weighted underlying holdings of the WisdomTree U.S. High Dividend Fund (Symbol: DHS) shows an impressive 10.9% of holdings on a weighted basis have experienced insider buying within the past six months.
AbbVie Inc (Symbol: ABBV), which makes up 4.29% of the WisdomTree U.S. High Dividend Fund (Symbol: DHS)... | AbbVie Inc (Symbol: ABBV), which makes up 4.29% of the WisdomTree U.S. High Dividend Fund (Symbol: DHS), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $40,752,886 worth of ABBV, making it the #4 largest holding. The table below de... | AbbVie Inc (Symbol: ABBV), which makes up 4.29% of the WisdomTree U.S. High Dividend Fund (Symbol: DHS), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $88.89 —... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $88.89 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 4.29% of the WisdomTree U.S. High Dividend Fund (Symbol: DHS), has seen 5 directors and officers purchase shares in the past six months, according to th... | AbbVie Inc (Symbol: ABBV), which makes up 4.29% of the WisdomTree U.S. High Dividend Fund (Symbol: DHS), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $40,752,886 worth of ABBV, making it the #4 largest holding. The table below de... |
24,760 | 2020-01-08 00:00:00 UTC | AbbVie To Create New Global Business Upon Completion Of Allergan Acquisition | ABBV | https://www.nasdaq.com/articles/abbvie-to-create-new-global-business-upon-completion-of-allergan-acquisition-2020-01-08 | null | null | (RTTNews) - AbbVie (ABBV) said that it will create a new global business, Allergan Aesthetics, and propose leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition.
Allergan Aesthetics will operate as a new global dedicated business with its own research... | She will oversee the worldwide operations, along with an experienced team of current Allergan leaders, and report directly to Richard Gonzalez, Chairman and Chief Executive Officer, AbbVie. The Eye Care and Specialty businesses - including BOTOX Therapeutics, Central Nervous System, Women's Health and Gastrointestinal ... | Strom will be named Senior Vice President, AbbVie and President, Global Allergan Aesthetics following completion of the Allergan acquisition. She will oversee the worldwide operations, along with an experienced team of current Allergan leaders, and report directly to Richard Gonzalez, Chairman and Chief Executive Offic... | (RTTNews) - AbbVie (ABBV) said that it will create a new global business, Allergan Aesthetics, and propose leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition. Strom will be named Senior Vice President, AbbVie and President, Global Allergan Aestheti... | Allergan Aesthetics will operate as a new global dedicated business with its own research and development function under the AbbVie umbrella. Strom will be named Senior Vice President, AbbVie and President, Global Allergan Aesthetics following completion of the Allergan acquisition. (RTTNews) - AbbVie (ABBV) said that ... |
24,761 | 2020-01-08 00:00:00 UTC | Better Buy: AbbVie vs. Biogen | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-01-08 | null | null | AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two pharma stocks that haven't performed well lately. Over the last 12 months, AbbVie's shares are down by 2%, while Biogen's stock is down by 10%. By contrast, the pharmaceutical industry -- as measured by the SPDR S&P Pharmaceuticals Index -- is up by 14% over the sam... | AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two pharma stocks that haven't performed well lately. Over the last 12 months, AbbVie's shares are down by 2%, while Biogen's stock is down by 10%. However, 2020 could be very different for both companies, as AbbVie is hoping its acquisition of Allergan (NYSE: AGN) pays... | However, 2020 could be very different for both companies, as AbbVie is hoping its acquisition of Allergan (NYSE: AGN) pays off, while Biogen is putting its hopes on its potential drug for Alzheimer's disease (AD), aducanumab. AbbVie CEO Richard Gonzalez said: With the planned acquisition of Allergan, we will be adding ... | However, 2020 could be very different for both companies, as AbbVie is hoping its acquisition of Allergan (NYSE: AGN) pays off, while Biogen is putting its hopes on its potential drug for Alzheimer's disease (AD), aducanumab. AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two pharma stocks that haven't performed wel... | Over the last 12 months, AbbVie's shares are down by 2%, while Biogen's stock is down by 10%. However, AbbVie is a more attractive dividend stock. AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two pharma stocks that haven't performed well lately. |
24,762 | 2020-01-07 00:00:00 UTC | AbbVie's Rheumatoid Arthritis Drug Receives Approval from Health Canada | ABBV | https://www.nasdaq.com/articles/abbvies-rheumatoid-arthritis-drug-receives-approval-from-health-canada-2020-01-07 | null | null | Pharmaceutical giant AbbVie (NYSE: ABBV) announced that Health Canada officially approved its rheumatoid arthritis (RA) drug Rinvoq. Canadians with moderate to severe cases of the condition who don't respond well to the more commonly prescribed treatment, methotrexate, can now receive Rinvoq instead.
Rinvoq is a daily ... | Pharmaceutical giant AbbVie (NYSE: ABBV) announced that Health Canada officially approved its rheumatoid arthritis (RA) drug Rinvoq. As patent protection for AbbVie's top drug, Humira, is expiring in 2023, the pharmaceutical giant hopes that drugs like Rinvoq will become successful enough to replace any lost revenue fr... | Pharmaceutical giant AbbVie (NYSE: ABBV) announced that Health Canada officially approved its rheumatoid arthritis (RA) drug Rinvoq. As patent protection for AbbVie's top drug, Humira, is expiring in 2023, the pharmaceutical giant hopes that drugs like Rinvoq will become successful enough to replace any lost revenue fr... | Pharmaceutical giant AbbVie (NYSE: ABBV) announced that Health Canada officially approved its rheumatoid arthritis (RA) drug Rinvoq. As patent protection for AbbVie's top drug, Humira, is expiring in 2023, the pharmaceutical giant hopes that drugs like Rinvoq will become successful enough to replace any lost revenue fr... | As patent protection for AbbVie's top drug, Humira, is expiring in 2023, the pharmaceutical giant hopes that drugs like Rinvoq will become successful enough to replace any lost revenue from Humira's loss of exclusivity. Pharmaceutical giant AbbVie (NYSE: ABBV) announced that Health Canada officially approved its rheuma... |
24,763 | 2020-01-07 00:00:00 UTC | Why Neurocrine Biosciences Soared 50.5% in 2019 | ABBV | https://www.nasdaq.com/articles/why-neurocrine-biosciences-soared-50.5-in-2019-2020-01-08 | null | null | What happened
After shares lost ground following a clinical trial failure in Tourette syndrome in December 2018, Neurocrine Biosciences (NASDAQ: NBIX) bounced back in 2019 with an eye-popping 50.5% return, according to S&P Global Market Intelligence.
The biotech's market-beating performance was supported by growing sal... | Royalties on Orilissa from AbbVie (NYSE: ABBV) also increased in 2019. The drug was approved for use in August 2018; AbbVie's Orilissa revenue improved 50% sequentially to $27 million in the third quarter, resulting in about $4 million in royalty revenue to Neurocrine in the period. What happened After shares lost grou... | Royalties on Orilissa from AbbVie (NYSE: ABBV) also increased in 2019. The drug was approved for use in August 2018; AbbVie's Orilissa revenue improved 50% sequentially to $27 million in the third quarter, resulting in about $4 million in royalty revenue to Neurocrine in the period. What happened After shares lost grou... | The drug was approved for use in August 2018; AbbVie's Orilissa revenue improved 50% sequentially to $27 million in the third quarter, resulting in about $4 million in royalty revenue to Neurocrine in the period. Royalties on Orilissa from AbbVie (NYSE: ABBV) also increased in 2019. The biotech's market-beating perform... | The drug was approved for use in August 2018; AbbVie's Orilissa revenue improved 50% sequentially to $27 million in the third quarter, resulting in about $4 million in royalty revenue to Neurocrine in the period. Royalties on Orilissa from AbbVie (NYSE: ABBV) also increased in 2019. The company filled 34,800 Ingrezza p... |
24,764 | 2020-01-07 00:00:00 UTC | Better Buy: Geron vs. Incyte | ABBV | https://www.nasdaq.com/articles/better-buy%3A-geron-vs.-incyte-2020-01-07 | null | null | Geron (NASDAQ: GERN) and Incyte (NASDAQ: INCY) live at opposite ends of the biotech spectrum. One company has no approved drug despite its best efforts. The other owns a drug garnering multiple approvals from the Food and Drug Administration (FDA). One biotech earns de minimis revenue and scrapes by through continually... | For instance, Reata Pharmaceuticals successfully regained rights to several drugs from AbbVie just before positive clinical trial data last year. Nearly two decades after its founding, three of Geron's academic collaborators won the Nobel Prize in 2009 for research on telomerase and its involvement in cancer, which val... | For instance, Reata Pharmaceuticals successfully regained rights to several drugs from AbbVie just before positive clinical trial data last year. The success stems from Jakafi, an approved drug for treating intermediate and high-risk myelofibrosis, polycythemia vera, and, most recently, steroid-refractory graft-versus-... | For instance, Reata Pharmaceuticals successfully regained rights to several drugs from AbbVie just before positive clinical trial data last year. Last year, Geron embarked on a three-year pivotal trial for its lead telomerase inhibitor called imetelstat. Geron faces headwinds Janssen Biotech, a subsidiary of Johnson & ... | For instance, Reata Pharmaceuticals successfully regained rights to several drugs from AbbVie just before positive clinical trial data last year. At Sept. 30, 2019, the company had $159.3 million. Five research analysts gave Geron a buy rating with price targets ranging from $3 to $5. |
24,765 | 2020-01-07 00:00:00 UTC | AbbVie: Health Canada Approves RINVOQ For Treatment Of Rheumatoid Arthritis | ABBV | https://www.nasdaq.com/articles/abbvie%3A-health-canada-approves-rinvoq-for-treatment-of-rheumatoid-arthritis-2020-01-07 | null | null | (RTTNews) - AbbVie (ABBV) announced that Health Canada has approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. RINVOQ is a 15 mg, once-daily oral medication in an extended-release tablet.
A... | (RTTNews) - AbbVie (ABBV) announced that Health Canada has approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. AbbVie said the approval from Health Canada was supported by efficacy and safe... | (RTTNews) - AbbVie (ABBV) announced that Health Canada has approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. AbbVie said the approval from Health Canada was supported by efficacy and safe... | (RTTNews) - AbbVie (ABBV) announced that Health Canada has approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. AbbVie said the approval from Health Canada was supported by efficacy and safe... | (RTTNews) - AbbVie (ABBV) announced that Health Canada has approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. AbbVie said the approval from Health Canada was supported by efficacy and safe... |
24,766 | 2020-01-06 00:00:00 UTC | Is Amarin Stock a Top Pick for 2020? | ABBV | https://www.nasdaq.com/articles/is-amarin-stock-a-top-pick-for-2020-2020-01-06 | null | null | Amarin (NASDAQ:) has had its share of ups and downs, particularly last month. While the rest of the market has been banging out new high after new high, the same cannot be said for Amarin stock.
Source: Pavel Kapysh / Shutterstock.com
Earlier this month, the stock was halted in midday trading for news pending. That cam... | Most notably, Bristol-Myers Squibb (NYSE:) buying Celgene for ~$74 billion and AbbVie (NYSE:) buying Allergan (NYSE:) for ~$63 billion come to mind. News was ultimately released after the close, leaving investors, traders and option holders (with weekly expirations on the line) in a frustrating position. Valuing Amarin... | Most notably, Bristol-Myers Squibb (NYSE:) buying Celgene for ~$74 billion and AbbVie (NYSE:) buying Allergan (NYSE:) for ~$63 billion come to mind. Ultimately, the company released good news though and shares were set to run higher on Monday. Still, this leaves the AMRN stock price trading at more than 11.2 times next... | Most notably, Bristol-Myers Squibb (NYSE:) buying Celgene for ~$74 billion and AbbVie (NYSE:) buying Allergan (NYSE:) for ~$63 billion come to mind. The price of AMRN stock is down about 20% from the Dec. 16 high, when shares began trading again. So what should investors make of Amarin stock? | Most notably, Bristol-Myers Squibb (NYSE:) buying Celgene for ~$74 billion and AbbVie (NYSE:) buying Allergan (NYSE:) for ~$63 billion come to mind. The price of AMRN stock is down about 20% from the Dec. 16 high, when shares began trading again. So what should investors make of Amarin stock? |
24,767 | 2020-01-05 00:00:00 UTC | Is Johnson & Johnson Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-johnson-johnson-stock-a-buy-2020-01-05 | null | null | Johnson & Johnson (NYSE: JNJ) didn't have a great year in 2019. Sure, the stock was up 13%. However, that wasn't even half the gain that the S&P 500 index delivered last year. J&J was bogged down by opioid-related litigation, more worries that its talc-based products contain asbestos, and anemic growth.
But it's not a ... | J&J's cancer drugs Imbruvica (which it comarkets with AbbVie) and Darzalex continue to enjoy strong momentum. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. Wall Street analysts project the company's earnings will grow by an average of less than 6% annually over th... | J&J's cancer drugs Imbruvica (which it comarkets with AbbVie) and Darzalex continue to enjoy strong momentum. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. So-so growth Investors who prefer strong growth probably won't be attracted to Johnson & Johnson. | J&J's cancer drugs Imbruvica (which it comarkets with AbbVie) and Darzalex continue to enjoy strong momentum. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. So-so growth Investors who prefer strong growth probably won't be attracted to Johnson & Johnson. | J&J's cancer drugs Imbruvica (which it comarkets with AbbVie) and Darzalex continue to enjoy strong momentum. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. But it's not a good idea to base an opinion about any stock on one problematic year, especially the stock of... |
24,768 | 2020-01-02 00:00:00 UTC | NOBL, TGT, ABBV, ADM: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/nobl-tgt-abbv-adm%3A-large-inflows-detected-at-etf-2020-01-02 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares ProShares S&P 500 Dividend Aristocrats ETF (Symbol: NOBL) where we have detected an approximate $79.4 million dollar inflow -- that's a 1.2% increase week over week in outstanding ... | Among the largest underlying components of NOBL, in trading today Target Corp (Symbol: TGT) is off about 0.9%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Archer Daniels Midland Co. (Symbol: ADM) is lower by about 0.5%. For a complete list of holdings, visit the NOBL Holdings page » The chart below shows the one ye... | Among the largest underlying components of NOBL, in trading today Target Corp (Symbol: TGT) is off about 0.9%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Archer Daniels Midland Co. (Symbol: ADM) is lower by about 0.5%. For a complete list of holdings, visit the NOBL Holdings page » The chart below shows the one ye... | Among the largest underlying components of NOBL, in trading today Target Corp (Symbol: TGT) is off about 0.9%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Archer Daniels Midland Co. (Symbol: ADM) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... | Among the largest underlying components of NOBL, in trading today Target Corp (Symbol: TGT) is off about 0.9%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Archer Daniels Midland Co. (Symbol: ADM) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... |
24,769 | 2020-01-02 00:00:00 UTC | Better Buy: Abbott Laboratories vs. Pfizer | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbott-laboratories-vs.-pfizer-2020-01-02 | null | null | Investors looking for large-cap, dividend-paying healthcare stocks have plenty of options. Whether it's large-scale drug manufacturers or medical technology providers, there's enough choice to suit whatever you're looking for.
Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE) both have large market valuations, sol... | Ever since splitting from AbbVie in 2013, the company has done quite well for itself. The company's new CEO, Albert Bourla, is implementing a major shift in corporate strategy, focusing on higher-margin products by spinning off well-known drug brands that have been dragging down revenue growth. If shedding its Upjohn d... | Ever since splitting from AbbVie in 2013, the company has done quite well for itself. However, they operate in different areas of the healthcare market, with Abbott developing diagnostic equipment while Pfizer focuses on developing new pharmaceutical candidates. Earlier in July, Pfizer announced that it was selling its... | Ever since splitting from AbbVie in 2013, the company has done quite well for itself. The company's best drug candidates, an anticoagulant called Eliquis and a breast cancer drug called lbrance, are also still staying with Pfizer. Thanks to some major acquisitions, including a $25 billion buyout of rival medical device... | Ever since splitting from AbbVie in 2013, the company has done quite well for itself. All three drugs have seen very strong growth rates, with Inlyta up 240%, Vyndaqel up 325%, and Xeljanz up 40% year over year in terms of sales. While medical device sales are Abbott's bread and butter, its total revenue is split among... |
24,770 | 2020-01-01 00:00:00 UTC | Is AbbVie's Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-abbvies-stock-a-buy-2020-01-01 | null | null | It's been a tough year for AbbVie (NYSE: ABBV) as the stock is closing 2019 not far from where it finished the year before. Question marks about the future of its business have made investors wary of investing in the company. However, given its poor performance in a year that's seen the Health Care Select SPDR Fund ris... | However, given its poor performance in a year that's seen the Health Care Select SPDR Fund rise by 21% and the S&P 500 index produce returns of around 29%, AbbVie could be an underrated buy for 2020, especially given some exciting opportunities ahead. AbbVie is currently trading at more than 40 times its earnings, but ... | According to the company's most recent earnings report, released in November, Humira accounted for 58% of AbbVie's top line over the past nine months. It's been a tough year for AbbVie (NYSE: ABBV) as the stock is closing 2019 not far from where it finished the year before. However, given its poor performance in a year... | The danger for AbbVie is that while the acquisition will add more revenue, it could also saddle the company with greater expenses that eat into its bottom line, which has been strong, with AbbVie posting a profit of more than $5.1 billion in each of the past four years. There's a great deal of uncertainty surrounding A... | According to the company's most recent earnings report, released in November, Humira accounted for 58% of AbbVie's top line over the past nine months. It's been a tough year for AbbVie (NYSE: ABBV) as the stock is closing 2019 not far from where it finished the year before. However, given its poor performance in a year... |
24,771 | 2019-12-30 00:00:00 UTC | Health Care Sector Update for 12/30/2019: SLGL,EARS,XFOR,ABBV,CBMG | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-12-30-2019%3A-slglearsxforabbvcbmg-2019-12-30 | null | null | Top Health Care Stocks
JNJ -0.25%
PFE -0.85%
ABT -0.57%
MRK -0.60%
AMGN -0.62%
Health care stocks extended their Monday declines, with the NYSE Health Care Index dropping slightly more than 0.6% while the shares of health care companies in the S&P 500 also were down just over 0.6% as a group. The Nasdaq Biotechnology i... | (-) X4 Pharmaceuticals (XFOR) was 1% lower Monday afternoon, giving back an early 3% spike that followed the immuno-oncology company saying it has started phase Ib testing of a combination of its mavorixafor drug candidate with Abbvie's (ABBV) ibrutinib cancer medication for the treatment of Waldenstrom's macroglobulin... | (-) X4 Pharmaceuticals (XFOR) was 1% lower Monday afternoon, giving back an early 3% spike that followed the immuno-oncology company saying it has started phase Ib testing of a combination of its mavorixafor drug candidate with Abbvie's (ABBV) ibrutinib cancer medication for the treatment of Waldenstrom's macroglobulin... | (-) X4 Pharmaceuticals (XFOR) was 1% lower Monday afternoon, giving back an early 3% spike that followed the immuno-oncology company saying it has started phase Ib testing of a combination of its mavorixafor drug candidate with Abbvie's (ABBV) ibrutinib cancer medication for the treatment of Waldenstrom's macroglobulin... | (-) X4 Pharmaceuticals (XFOR) was 1% lower Monday afternoon, giving back an early 3% spike that followed the immuno-oncology company saying it has started phase Ib testing of a combination of its mavorixafor drug candidate with Abbvie's (ABBV) ibrutinib cancer medication for the treatment of Waldenstrom's macroglobulin... |
24,772 | 2019-12-30 00:00:00 UTC | ABBV: Insiders vs. Shorts | ABBV | https://www.nasdaq.com/articles/abbv%3A-insiders-vs.-shorts-2019-12-30 | null | null | The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc (Symbol: ABBV) is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to... | AbbVie Inc (Symbol: ABBV) has something relatively rare for a stock with this much short interest, that being insiders taking the other side of the trade. 07/30/2019 Roxanne S. Austin Director 10,000 $66.35 $663,500.00 07/29/2019 Henry O. Gosebruch EVP, Chief Strategy Officer 30,000 $67.28 $2,018,385.00 08/01/2019 Roxa... | The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc (Symbol: ABBV) is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." In the case of AbbVie Inc (Symbol: ABBV), the total short interest at the 04/15/2019 settlement date was 27,575,8... | In the case of AbbVie Inc (Symbol: ABBV), the total short interest at the 04/15/2019 settlement date was 27,575,807 shares, which compares to the average daily trading volume of just 4,952,645 shares, for a "days to cover" ratio of 5.57. At the present levels of short interest, if from this point forward every single A... | The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc (Symbol: ABBV) is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." In the case of AbbVie Inc (Symbol: ABBV), the total short interest at the 04/15/2019 settlement date was 27,575,8... |
24,773 | 2019-12-30 00:00:00 UTC | 7 High-Yield Dividend Stocks for Growth and Income in the 2020s | ABBV | https://www.nasdaq.com/articles/7-high-yield-dividend-stocks-for-growth-and-income-in-the-2020s-2019-12-30 | null | null | In a year where the S&P 500 grew by nearly 30%, dividend stocks often receive less attention. Despite this, with bank depositors often struggling to earn 1% per year in interest income, they remain attractive stocks to buy.
Moreover, anyone who has followed the stock market for any length of time knows that some years ... | As the company absorbs Allergan and new drugs replace the revenue from Humira, ABBV stock should continue its march higher. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) is one of the dividend stocks that may have finally begun its long-awaited recovery. The Allergan buy now appears to have served ... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) is one of the dividend stocks that may have finally begun its long-awaited recovery. The Allergan buy now appears to have served as the low point of ABBV stock. AbbVie now trades at about $89 per share. | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) is one of the dividend stocks that may have finally begun its long-awaited recovery. The Allergan buy now appears to have served as the low point of ABBV stock. AbbVie now trades at about $89 per share. | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) is one of the dividend stocks that may have finally begun its long-awaited recovery. The Allergan buy now appears to have served as the low point of ABBV stock. AbbVie now trades at about $89 per share. |
24,774 | 2019-12-30 00:00:00 UTC | 5 Cheap High-Yield Dividend Stocks with Growing Dividends | ABBV | https://www.nasdaq.com/articles/5-cheap-high-yield-dividend-stocks-with-growing-dividends-2019-12-30 | null | null | When writing this article, my plan was to find an ideal list of high-yield stock that is expected to have a higher dividend next year. To make my list, the stocks would also have to have a very low price-to-earnings ratio. The following is a list of five such stocks that I found.
The average dividend yield of the . So ... | Dividend Stocks: AbbVie (ABBV) Source: Mark R. Hake Expected Dividend Growth Next Year: +10.3% Dividend Yield: 4.8% Forward P/E Ratio: 9x AbbVie (NYSE:) is a $130 billion market value drug manufacturing company. In addition, ABBV stock is very cheap. In 2020, expected earnings of $9.91 per share put ABBV stock at a P/E... | Dividend Stocks: AbbVie (ABBV) Source: Mark R. Hake Expected Dividend Growth Next Year: +10.3% Dividend Yield: 4.8% Forward P/E Ratio: 9x AbbVie (NYSE:) is a $130 billion market value drug manufacturing company. In addition, ABBV stock is very cheap. In 2020, expected earnings of $9.91 per share put ABBV stock at a P/E... | Dividend Stocks: AbbVie (ABBV) Source: Mark R. Hake Expected Dividend Growth Next Year: +10.3% Dividend Yield: 4.8% Forward P/E Ratio: 9x AbbVie (NYSE:) is a $130 billion market value drug manufacturing company. In addition, ABBV stock is very cheap. In 2020, expected earnings of $9.91 per share put ABBV stock at a P/E... | Dividend Stocks: AbbVie (ABBV) Source: Mark R. Hake Expected Dividend Growth Next Year: +10.3% Dividend Yield: 4.8% Forward P/E Ratio: 9x AbbVie (NYSE:) is a $130 billion market value drug manufacturing company. In addition, ABBV stock is very cheap. In 2020, expected earnings of $9.91 per share put ABBV stock at a P/E... |
24,775 | 2019-12-30 00:00:00 UTC | 5 Stocks to Buy in January | ABBV | https://www.nasdaq.com/articles/5-stocks-to-buy-in-january-2019-12-30 | null | null | The stock market was scorching hot in 2019. The S&P 500 gained about 30%, marking its best year since 1997. Several factors helped power the market to new highs, including rate cuts by the Federal Reserve and an easing of trade tensions between the U.S. and China.
This next year, however, likely won't be quite so kind ... | The closest major rival is AbbVie (NYSE: ABBV), which is evaluating a triple-drug CF combo in an early-stage clinical study. But Vertex has a massive head start over AbbVie. Keith Speights owns shares of AbbVie, Facebook, SPDR S&P 500, and Vertex Pharmaceuticals. | The closest major rival is AbbVie (NYSE: ABBV), which is evaluating a triple-drug CF combo in an early-stage clinical study. But Vertex has a massive head start over AbbVie. Keith Speights owns shares of AbbVie, Facebook, SPDR S&P 500, and Vertex Pharmaceuticals. | The closest major rival is AbbVie (NYSE: ABBV), which is evaluating a triple-drug CF combo in an early-stage clinical study. But Vertex has a massive head start over AbbVie. Keith Speights owns shares of AbbVie, Facebook, SPDR S&P 500, and Vertex Pharmaceuticals. | The closest major rival is AbbVie (NYSE: ABBV), which is evaluating a triple-drug CF combo in an early-stage clinical study. But Vertex has a massive head start over AbbVie. Keith Speights owns shares of AbbVie, Facebook, SPDR S&P 500, and Vertex Pharmaceuticals. |
24,776 | 2019-12-30 00:00:00 UTC | 3 Big Pharma Stocks That Pay Big Dividends | ABBV | https://www.nasdaq.com/articles/3-big-pharma-stocks-that-pay-big-dividends-2019-12-30 | null | null | The past year has been great for stocks across the board, but that's made it awfully hard to find reliable dividend-paying stocks that offer satisfactory yields. The average dividend yield for stocks in the S&P 500 index has dwindled to just 1.8% at the moment, but there are still a few big pharmaceutical companies wit... | Two out of three ain't bad While dividends from Pfizer and Gilead Sciences will probably continue rising for the foreseeable future, it's probably best to ignore the higher yield that AbbVie offers at the moment. AbbVie (NYSE: ABBV) 5.3% 48% Pfizer (NYSE: PFE) 3.9% 74% Gilead Sciences (NASDAQ: GILD) 3.8% 39% Data sourc... | AbbVie (NYSE: ABBV) 5.3% 48% Pfizer (NYSE: PFE) 3.9% 74% Gilead Sciences (NASDAQ: GILD) 3.8% 39% Data source: Yahoo! Gilead Sciences: Making a comeback Fierce competition from AbbVie for patients with hepatitis C virus (HCV) has been a disaster for Gilead Sciences in recent years, but the pain is nearly over. AbbVie: A... | Humira sales reached $14.4 billion in the first nine months of 2019, which worked out to 59% of net revenue, but adding Allergan's products to AbbVie's lineup should reduce that figure to around 40% of total revenue based on 2019 sales forecasts. Two out of three ain't bad While dividends from Pfizer and Gilead Science... | Humira sales reached $14.4 billion in the first nine months of 2019, which worked out to 59% of net revenue, but adding Allergan's products to AbbVie's lineup should reduce that figure to around 40% of total revenue based on 2019 sales forecasts. Two out of three ain't bad While dividends from Pfizer and Gilead Science... |
24,777 | 2019-12-28 00:00:00 UTC | A $20 Billion Sweet Spot in Biotech | ABBV | https://www.nasdaq.com/articles/a-%2420-billion-sweet-spot-in-biotech-2019-12-28 | null | null | This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN). Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, of course, an acquirer emerges. ... | AbbVie remains in the thick of its $63 billion deal with Allergan. Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, of course, an acquirer emerges. Adcetris, Seattle Genetics' first approved... | AbbVie remains in the thick of its $63 billion deal with Allergan. Adcetris, Seattle Genetics' first approved cancer drug, continued to reach record sales levels each quarter, representing growth between 30% and 42% compared to the corresponding periods in 2018. Earlier this month, the company highlighted promising cli... | AbbVie remains in the thick of its $63 billion deal with Allergan. This week the U.S. Food and Drug Administration granted accelerated approval three months ahead of schedule for Seattle Genetics' drug Padcev to treat the most common form of bladder cancer. While Seattle Genetics feverishly readies tucatinib's New Drug... | AbbVie remains in the thick of its $63 billion deal with Allergan. Earlier this month, the company highlighted promising clinical trials results for a novel breast cancer drug called tucatinib. Seattle Genetics is a stock to own for 2020. |
24,778 | 2019-12-28 00:00:00 UTC | Can Johnson & Johnson Break Out In 2020? | ABBV | https://www.nasdaq.com/articles/can-johnson-johnson-break-out-in-2020-2019-12-28 | null | null | Johnson & Johnson (NYSE: JNJ) enjoyed an excellent run from 2010 to 2017, climbing from $63 to $140 before entering a more volatile period over the past two years. Since then, the stock has bounced between $120 and $147, and it sits closer to the top of that range as 2019 comes to an end. Investors who rode that wave h... | Previous top-seller Remicade is experiencing declining sales due to competition, and pipeline products from AbbVie (NYSE: ABBV) could threaten Johnson & Johnson's immunology group with pending U.S. Food and Drug Administration approvals. Potential regulatory changes and competition threaten the segment, and heavy inves... | Previous top-seller Remicade is experiencing declining sales due to competition, and pipeline products from AbbVie (NYSE: ABBV) could threaten Johnson & Johnson's immunology group with pending U.S. Food and Drug Administration approvals. Johnson & Johnson operates a unique combination of businesses The branded company'... | Previous top-seller Remicade is experiencing declining sales due to competition, and pipeline products from AbbVie (NYSE: ABBV) could threaten Johnson & Johnson's immunology group with pending U.S. Food and Drug Administration approvals. Johnson & Johnson operates a unique combination of businesses The branded company'... | Previous top-seller Remicade is experiencing declining sales due to competition, and pipeline products from AbbVie (NYSE: ABBV) could threaten Johnson & Johnson's immunology group with pending U.S. Food and Drug Administration approvals. Finally, Johnson & Johnson has a consumer health products segment that contributes... |
24,779 | 2019-12-25 00:00:00 UTC | 3 Top Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-to-buy-right-now-2019-12-25 | null | null | The end of one year and the start of another gives us a good opportunity to review our investment successes and failures over the last 12 months. It also provides a platform to see where we're going and choose our investments for what's sure to be a raucous year in the market.
Dividend stocks offer some of the best way... | Pharmaceutical company AbbVie (NYSE: ABBV) lets investors enjoy both: It has outpaced the gains of the S&P 500 since its spinoff from Abbott Labs in 2013 while also raising its dividend by an average of almost 25% a year. The risk with AbbVie has been its reliance upon its arthritis treatment Humira, which generates ar... | Pharmaceutical company AbbVie (NYSE: ABBV) lets investors enjoy both: It has outpaced the gains of the S&P 500 since its spinoff from Abbott Labs in 2013 while also raising its dividend by an average of almost 25% a year. The risk with AbbVie has been its reliance upon its arthritis treatment Humira, which generates ar... | Pharmaceutical company AbbVie (NYSE: ABBV) lets investors enjoy both: It has outpaced the gains of the S&P 500 since its spinoff from Abbott Labs in 2013 while also raising its dividend by an average of almost 25% a year. The risk with AbbVie has been its reliance upon its arthritis treatment Humira, which generates ar... | Pharmaceutical company AbbVie (NYSE: ABBV) lets investors enjoy both: It has outpaced the gains of the S&P 500 since its spinoff from Abbott Labs in 2013 while also raising its dividend by an average of almost 25% a year. The risk with AbbVie has been its reliance upon its arthritis treatment Humira, which generates ar... |
24,780 | 2019-12-24 00:00:00 UTC | 3 Blockbuster Cancer Drug Launches to Watch in 2020 | ABBV | https://www.nasdaq.com/articles/3-blockbuster-cancer-drug-launches-to-watch-in-2020-2019-12-24 | null | null | This has been an outstanding year for biotech stocks, and 2020 could be even better thanks to a slate of bonafide life-savers that hit pharmacy shelves months ahead of schedule.
The FDA approved dozens of drugs in 2019, but the agency rushed to greenlight these new cancer therapies much sooner than expected. Here's wh... | Another BTK-inhibitor marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) called Imbruvica earned approval to treat the same group of patients in 2013 after shrinking tumors just 66% of the time. During the first nine months of 2019, J&J and AbbVie reported Imbruvica sales that reached a combined $5.9 bil... | Another BTK-inhibitor marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) called Imbruvica earned approval to treat the same group of patients in 2013 after shrinking tumors just 66% of the time. During the first nine months of 2019, J&J and AbbVie reported Imbruvica sales that reached a combined $5.9 bil... | Another BTK-inhibitor marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) called Imbruvica earned approval to treat the same group of patients in 2013 after shrinking tumors just 66% of the time. During the first nine months of 2019, J&J and AbbVie reported Imbruvica sales that reached a combined $5.9 bil... | Another BTK-inhibitor marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) called Imbruvica earned approval to treat the same group of patients in 2013 after shrinking tumors just 66% of the time. During the first nine months of 2019, J&J and AbbVie reported Imbruvica sales that reached a combined $5.9 bil... |
24,781 | 2019-12-22 00:00:00 UTC | Why I'd Avoid These Marijuana ETNs Like the Plague | ABBV | https://www.nasdaq.com/articles/why-id-avoid-these-marijuana-etns-like-the-plague-2019-12-22 | null | null | You can count the number of exchange-traded funds (ETFs) focused on the cannabis industry using your fingers. Until a couple of weeks ago, though, there weren't any marijuana exchange-traded noted (ETNs), which, unlike ETFs, don't hold positions in stocks but instead are unsecured debt securities issued by a financial ... | Over half of the MicroSectors North American Cannabis Index is tied to just five stocks: AbbVie, Agilent, Mettler-Toledo, Thermo Fisher Scientific, and Waters Corporation. AbbVie qualifies probably due to its marketing of Marinol, an FDA-approved drug that contains a synthetic cannabinoid. Learn more Keith Speights own... | Over half of the MicroSectors North American Cannabis Index is tied to just five stocks: AbbVie, Agilent, Mettler-Toledo, Thermo Fisher Scientific, and Waters Corporation. AbbVie qualifies probably due to its marketing of Marinol, an FDA-approved drug that contains a synthetic cannabinoid. Learn more Keith Speights own... | Over half of the MicroSectors North American Cannabis Index is tied to just five stocks: AbbVie, Agilent, Mettler-Toledo, Thermo Fisher Scientific, and Waters Corporation. AbbVie qualifies probably due to its marketing of Marinol, an FDA-approved drug that contains a synthetic cannabinoid. Learn more Keith Speights own... | Over half of the MicroSectors North American Cannabis Index is tied to just five stocks: AbbVie, Agilent, Mettler-Toledo, Thermo Fisher Scientific, and Waters Corporation. AbbVie qualifies probably due to its marketing of Marinol, an FDA-approved drug that contains a synthetic cannabinoid. Learn more Keith Speights own... |
24,782 | 2019-12-22 00:00:00 UTC | Why 2020 Should Be the Biggest Year Yet for CRISPR Gene-Editing Stocks | ABBV | https://www.nasdaq.com/articles/why-2020-should-be-the-biggest-year-yet-for-crispr-gene-editing-stocks-2019-12-22 | null | null | Has there been a lot of hype about CRISPR gene editing? Absolutely. But while the hype might have been overdone in some cases, the reality is that there's significant potential for CRISPR (which stands for "clustered regularly interspaced short palindromic repeats") to transform the way many diseases are treated.
2019 ... | You could also throw AbbVie into the mix, since it's in the process of acquiring Allergan. For option 3, the SPDR S&P Biotech ETF's holdings include Editas, Intellia, Vertex, Regeneron, and AbbVie. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb... | See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, Editas Medicine, SPDR S&P Biotech, and Vertex Pharmaceuticals. You could also throw AbbVie into the mix, since it's in the process of acquiring Allergan. For option 3, the SPDR S&P Biotech ETF's h... | You could also throw AbbVie into the mix, since it's in the process of acquiring Allergan. For option 3, the SPDR S&P Biotech ETF's holdings include Editas, Intellia, Vertex, Regeneron, and AbbVie. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb... | You could also throw AbbVie into the mix, since it's in the process of acquiring Allergan. For option 3, the SPDR S&P Biotech ETF's holdings include Editas, Intellia, Vertex, Regeneron, and AbbVie. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb... |
24,783 | 2019-12-22 00:00:00 UTC | 20 High-Yield Dividend Stocks to Buy in 2020 | ABBV | https://www.nasdaq.com/articles/20-high-yield-dividend-stocks-to-buy-in-2020-2019-12-22 | null | null | A new year is on the way. With it comes plenty of excitement... and perhaps some nervousness for investors. No one knows what the stock market will do in 2020. After the longest bull run ever and the inherent uncertainty in a presidential election year, investors can't be blamed for being at least a little apprehensive... | Although AbbVie faces headwinds for its top-selling drug Humira, the rest of its lineup plus its pending acquisition of Allergan should put the company in great shape to keep the dividends flowing. AbbVie AbbVie (NYSE: ABBV) offers a dividend that yields nearly 5.3%. See the 10 stocks *Stock Advisor returns as of Decem... | AbbVie AbbVie (NYSE: ABBV) offers a dividend that yields nearly 5.3%. Although AbbVie faces headwinds for its top-selling drug Humira, the rest of its lineup plus its pending acquisition of Allergan should put the company in great shape to keep the dividends flowing. See the 10 stocks *Stock Advisor returns as of Decem... | AbbVie AbbVie (NYSE: ABBV) offers a dividend that yields nearly 5.3%. Although AbbVie faces headwinds for its top-selling drug Humira, the rest of its lineup plus its pending acquisition of Allergan should put the company in great shape to keep the dividends flowing. See the 10 stocks *Stock Advisor returns as of Decem... | AbbVie AbbVie (NYSE: ABBV) offers a dividend that yields nearly 5.3%. Although AbbVie faces headwinds for its top-selling drug Humira, the rest of its lineup plus its pending acquisition of Allergan should put the company in great shape to keep the dividends flowing. See the 10 stocks *Stock Advisor returns as of Decem... |
24,784 | 2019-12-20 00:00:00 UTC | Noteworthy Friday Option Activity: C, ABBV, VLO | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-c-abbv-vlo-2019-12-20 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Citigroup Inc (Symbol: C), where a total of 70,124 contracts have traded so far, representing approximately 7.0 million underlying shares. That amounts to about 63.4% of C's average daily trading volume over the past... | Particularly high volume was seen for the $77.50 strike call option expiring January 17, 2020, with 4,698 contracts trading so far today, representing approximately 469,800 underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $77.50 strike highlighted in orange: AbbVie In... | Particularly high volume was seen for the $77.50 strike call option expiring January 17, 2020, with 4,698 contracts trading so far today, representing approximately 469,800 underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $77.50 strike highlighted in orange: AbbVie In... | Particularly high volume was seen for the $77.50 strike call option expiring January 17, 2020, with 4,698 contracts trading so far today, representing approximately 469,800 underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $77.50 strike highlighted in orange: AbbVie In... | Particularly high volume was seen for the $77.50 strike call option expiring January 17, 2020, with 4,698 contracts trading so far today, representing approximately 469,800 underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $77.50 strike highlighted in orange: AbbVie In... |
24,785 | 2019-12-19 00:00:00 UTC | 2 Must-Own Dividend Growth Stocks in 2020 | ABBV | https://www.nasdaq.com/articles/2-must-own-dividend-growth-stocks-in-2020-2019-12-19 | null | null | Companies that regularly increase their dividends -- a.k.a. dividend growth stocks -- tend to be excellent wealth creators for long-term investors. That said, it's not exactly easy to unearth quality dividend stocks worth holding for lengthy periods of time.
Which dividend growth stocks should patient investors have o... | AbbVie's megamerger with Allergan should provide another powerful boost to the company's free cash flows post-transaction and lower the impact of Humira's eventual decline early in the next decade. The pharmaceutical giants AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two names that could produce market-b... | The pharmaceutical giants AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two names that could produce market-beating returns for the next decade and beyond. AbbVie: A proven cash cow for income investors Since its inception as a spinoff from Abbott Laboratories, AbbVie has averaged an annual 24.7% hike to i... | Even though AbbVie's sky-high payout ratio of 183% suggests otherwise, there are two clear-cut reasons to have faith in the drugmaker's ability to retain its status as a Dividend Aristocrat for years to come: AbbVie's highly diversified growth portfolio -- consisting of the hematology/oncology medicines Imbruvica and V... | The pharmaceutical giants AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two names that could produce market-beating returns for the next decade and beyond. AbbVie: A proven cash cow for income investors Since its inception as a spinoff from Abbott Laboratories, AbbVie has averaged an annual 24.7% hike to i... |
24,786 | 2019-12-18 00:00:00 UTC | ABBV Crosses Above Average Analyst Target | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-average-analyst-target-2019-12-18 | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.00, changing hands for $90.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a h... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.00, changing hands for $90.08/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.00, changing hands for $90.08/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | There are 7 different analyst targets contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. And so with ABBV crossing above that average target price of $90.00/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for ... | There are 7 different analyst targets contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $90.00, changing hands for $90.08/share. But the whole reason t... |
24,787 | 2019-12-17 00:00:00 UTC | 5 Large-Cap Dividend Stocks to Buy | ABBV | https://www.nasdaq.com/articles/5-large-cap-dividend-stocks-to-buy-2019-12-17 | null | null | U.S. equities are powering higher thanks to a the combined tailwinds of seasonal strength, a “Phase 1” trade deal between the United States and China, and ongoing monetary policy support from the Federal Reserve and other global central banks. All the major indices are stretching to new record highs, setting the stage ... | AbbVie (ABBV) Drugmaker AbbVie (NYSE:) is poised to move up and over its November high, setting the stage for a rally back to highs not seen since early 2017. Healthcare stocks have recently been swinging back into favor, benefiting stocks like ABBV as the national dialogue around single-payer healthcare has died down ... | AbbVie (ABBV) Drugmaker AbbVie (NYSE:) is poised to move up and over its November high, setting the stage for a rally back to highs not seen since early 2017. Healthcare stocks have recently been swinging back into favor, benefiting stocks like ABBV as the national dialogue around single-payer healthcare has died down ... | AbbVie (ABBV) Drugmaker AbbVie (NYSE:) is poised to move up and over its November high, setting the stage for a rally back to highs not seen since early 2017. Healthcare stocks have recently been swinging back into favor, benefiting stocks like ABBV as the national dialogue around single-payer healthcare has died down ... | AbbVie (ABBV) Drugmaker AbbVie (NYSE:) is poised to move up and over its November high, setting the stage for a rally back to highs not seen since early 2017. Healthcare stocks have recently been swinging back into favor, benefiting stocks like ABBV as the national dialogue around single-payer healthcare has died down ... |
24,788 | 2019-12-16 00:00:00 UTC | Is Amarin a $20 Billion Stock? | ABBV | https://www.nasdaq.com/articles/is-amarin-a-%2420-billion-stock-2019-12-16 | null | null | Trading in shares of Amarin (NASDAQ: AMRN) was halted on Friday when the stock started to take off in anticipation of good news from the U.S. Food and Drug Administration. Later in the day, the FDA provided an early holiday present to Amarin investors: the revised label the company had been seeking was approved.
The Na... | Consider AbbVie, for instance. Trading in shares of Amarin (NASDAQ: AMRN) was halted on Friday when the stock started to take off in anticipation of good news from the U.S. Food and Drug Administration. Later in the day, the FDA provided an early holiday present to Amarin investors: the revised label the company had be... | Consider AbbVie, for instance. It was widely expected that the FDA would allow Amarin to start marketing its drug to a much wider class of patients, and on Friday, the FDA delivered: "FDA approves use of drug to reduce risk of cardiovascular events in certain patient groups." The company wanted to expand the label to t... | Consider AbbVie, for instance. Indeed, according to FiercePharma, market chatter is now valuing the company at a $20 billion market cap, or $55 a share, if the company is acquired. It was widely expected that the FDA would allow Amarin to start marketing its drug to a much wider class of patients, and on Friday, the FD... | Consider AbbVie, for instance. In short, the number of people who might be prescribed Vascepa is very high -- in the tens of millions just in this country. If the drug is prescribed to 10% of this group, it's a $4.5 billion drug. |
24,789 | 2019-12-16 00:00:00 UTC | Is AbbVie’s Dividend Capable Of Long-Term Growth? | ABBV | https://www.nasdaq.com/articles/is-abbvies-dividend-capable-of-long-term-growth-2019-12-16 | null | null | Nearly 20 years ago on Dec. 15, 2000, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) announced its $6.9 billion acquisition of Knoll Pharmaceuticals, a subsidiary of chemical giant BASF. At that time, no one knew that Knoll housed a drug, still in clinical development, that would one day become... | The impact of these generics entering the market can be seen in AbbVie's third-quarter earnings release which showed international sales of Humira declining by 32%. Allergan will bring over $15 billion in revenues to AbbVie and in the process reduce overall Humira exposure to less than 40% of total sales, still signifi... | Last year, U.S. sales of Humira were $13.7 billion, or roughly 42% of AbbVie's total global sales. The approaching 2023 patent cliff looms for investors While investors wait for more clarity surrounding AbbVie's earnings power post the Humira 2023 loss of exclusivity, a dividend yield of 5.5%, which was increased by 10... | So in other words, AbbVie is viewing Allergan as a similar-sized asset that will replace the lost sales from Humira; and Humira will pay for it. The approaching 2023 patent cliff looms for investors While investors wait for more clarity surrounding AbbVie's earnings power post the Humira 2023 loss of exclusivity, a div... | So in other words, AbbVie is viewing Allergan as a similar-sized asset that will replace the lost sales from Humira; and Humira will pay for it. The medical device side retained the name Abbott Labs and the pharmaceutical business was spun-off to shareholders and the new company was named AbbVie (NYSE: ABBV). Humira's ... |
24,790 | 2019-12-15 00:00:00 UTC | Better Buy: AbbVie vs. Merck | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-merck-2019-12-15 | null | null | AbbVie (NYSE: ABBV) ranks as one of the biggest pharmaceutical stocks on the market. But it's still a lot smaller than Merck (NYSE: MRK). Bigger has proven to be better this year, with AbbVie's stock performance trailing well behind Merck's.
But which of these pharma stocks is the better pick for long-term investors lo... | AbbVie's top-selling drug, Humira, already faces biosimilar competition in Europe that's quickly eroding revenue. Remember that Wall Street thinks that Merck will deliver much stronger earnings growth over the next five years than AbbVie will -- and that view is probably right. AbbVie (NYSE: ABBV) ranks as one of the b... | Growth prospects Wall Street thinks that Merck's growth prospects look better than AbbVie's over the next five years. However, analysts think Allergan's growth prospects are even lower than AbbVie's, so the deal probably won't work miracles for AbbVie's growth story. AbbVie's shares trade at only nine times expected ea... | Growth prospects Wall Street thinks that Merck's growth prospects look better than AbbVie's over the next five years. However, analysts think Allergan's growth prospects are even lower than AbbVie's, so the deal probably won't work miracles for AbbVie's growth story. Remember that Wall Street thinks that Merck will del... | AbbVie's shares trade at only nine times expected earnings compared to Merck's forward earnings multiple of 16. AbbVie (NYSE: ABBV) ranks as one of the biggest pharmaceutical stocks on the market. Bigger has proven to be better this year, with AbbVie's stock performance trailing well behind Merck's. |
24,791 | 2019-12-15 00:00:00 UTC | 3 Companies That Are Raising Their Dividends | ABBV | https://www.nasdaq.com/articles/3-companies-that-are-raising-their-dividends-2019-12-15 | null | null | As the year comes to a close, income investors are thinking about more than just the upcoming holidays and New Year's Eve parties. They also have their dividend stocks in mind, since many publicly traded companies declare raises around this time.
In that spirit, here are three dividend stocks that are about to make the... | AbbVie Raiser No. 2 on our list is AbbVie (NYSE: ABBV), one of the small number of pharmaceutical stocks on the Dividend Aristocrats roster. This was a blast of good news in a year that hasn't seen a lot of it for AbbVie. | AbbVie Raiser No. 2 on our list is AbbVie (NYSE: ABBV), one of the small number of pharmaceutical stocks on the Dividend Aristocrats roster. This was a blast of good news in a year that hasn't seen a lot of it for AbbVie. | But Humira biosimilars won't be introduced in the U.S. for a few years yet, so AbbVie's current cash cow is hanging on (its global sales slumped only 3.7% year over year in the company's Q3). AbbVie Raiser No. 2 on our list is AbbVie (NYSE: ABBV), one of the small number of pharmaceutical stocks on the Dividend Aristoc... | AbbVie's new payout, which is to be dispensed Feb. 14 to investors of record as of Jan. 15, would yield 5.4% at the current stock price. AbbVie Raiser No. 2 on our list is AbbVie (NYSE: ABBV), one of the small number of pharmaceutical stocks on the Dividend Aristocrats roster. |
24,792 | 2019-12-15 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Joel Greenblatt - 12/15/2019 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joel-greenblatt-12-15-2019-2019-12-15 | null | null | The following are the top rated Healthcare stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Biotechnology ... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Molina Healthcare, Inc. offers Medicaid-related so... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of June 30, 2016, the Pharmaceutical Distribution segment consists o... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Its products are focused on treating conditions, such as chronic autoim... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea'... |
24,793 | 2019-12-15 00:00:00 UTC | 5 High-Yield Dividend Stocks to Watch | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-2019-12-15 | null | null | If you're an income-oriented investor, you probably like dividend stocks for their steady payouts. But no investor minds profiting from solid growth on top of nice dividends.
Can you get both high dividend yields and meaningful share appreciation in the market today? I think so. Here are five high-yield dividend stock... | AbbVie AbbVie's (NYSE: ABBV) dividend current yields nearly 5.5%. AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). Although AbbVie's year-to-date performance has been dismal, I look for 2020 to be a better year for the stock. | AbbVie AbbVie's (NYSE: ABBV) dividend current yields nearly 5.5%. AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). Although AbbVie's year-to-date performance has been dismal, I look for 2020 to be a better year for the stock. | AbbVie AbbVie's (NYSE: ABBV) dividend current yields nearly 5.5%. AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). Although AbbVie's year-to-date performance has been dismal, I look for 2020 to be a better year for the stock. | AbbVie AbbVie's (NYSE: ABBV) dividend current yields nearly 5.5%. AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). Although AbbVie's year-to-date performance has been dismal, I look for 2020 to be a better year for the stock. |
24,794 | 2019-12-13 00:00:00 UTC | ProShares ProShares S&P 500 Dividend Aristocrats ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/proshares-proshares-sp-500-dividend-aristocrats-etf-experiences-big-inflow-2019-12-13 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares ProShares S&P 500 Dividend Aristocrats ETF (Symbol: NOBL) where we have detected an approximate $60.3 million dollar inflow -- that's a 1.0% increase week over week in outstanding ... | Among the largest underlying components of NOBL, in trading today Leggett & Platt, Inc. (Symbol: LEG) is off about 0.3%, Target Corp (Symbol: TGT) is off about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.5%. For a complete list of holdings, visit the NOBL Holdings page » The chart below shows the one year p... | Among the largest underlying components of NOBL, in trading today Leggett & Platt, Inc. (Symbol: LEG) is off about 0.3%, Target Corp (Symbol: TGT) is off about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.5%. For a complete list of holdings, visit the NOBL Holdings page » The chart below shows the one year p... | Among the largest underlying components of NOBL, in trading today Leggett & Platt, Inc. (Symbol: LEG) is off about 0.3%, Target Corp (Symbol: TGT) is off about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of NOBL, in trading today Leggett & Platt, Inc. (Symbol: LEG) is off about 0.3%, Target Corp (Symbol: TGT) is off about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... |
24,795 | 2019-12-12 00:00:00 UTC | Noteworthy Thursday Option Activity: MAS, ABBV, C | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-mas-abbv-c-2019-12-12 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Masco Corp. (Symbol: MAS), where a total of 11,612 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 50% of MAS's average daily trading volume over the past... | Especially high volume was seen for the $90 strike call option expiring January 17, 2020, with 5,724 contracts trading so far today, representing approximately 572,400 underlying shares of ABBV. Below is a chart showing MAS's trailing twelve month trading history, with the $47 strike highlighted in orange: AbbVie Inc (... | Below is a chart showing MAS's trailing twelve month trading history, with the $47 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 34,475 contracts, representing approximately 3.4 million underlying shares or approximately 49.2% of ABBV's average daily trading volume over the past ... | Below is a chart showing MAS's trailing twelve month trading history, with the $47 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 34,475 contracts, representing approximately 3.4 million underlying shares or approximately 49.2% of ABBV's average daily trading volume over the past ... | Below is a chart showing MAS's trailing twelve month trading history, with the $47 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 34,475 contracts, representing approximately 3.4 million underlying shares or approximately 49.2% of ABBV's average daily trading volume over the past ... |
24,796 | 2019-12-11 00:00:00 UTC | Best ETFs for 2020: The AdvisorShares Vice ETF Is a Long-Term Winner | ABBV | https://www.nasdaq.com/articles/best-etfs-for-2020%3A-the-advisorshares-vice-etf-is-a-long-term-winner-2019-12-11 | null | null | This article is a part of InvestorPlace.com’s Best ETFs for 2020 contest. The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:).
This year was a peculiar one for marijuana stocks. Early on, hopes (and stocks) ran high on the idea that major growth was guaranteed in the cannabis space. B... | These holdings include: Thermo Fisher Scientific (NYSE:), Abbott Laboratories (NYSE:) and Abbvie (NYSE:). The core idea behind this exchange-traded fund is that in good times or bad, people will always seek “sinful” indulgences like pot, alcohol and tobacco. Luckily for investors who are concerned about too much direct... | These holdings include: Thermo Fisher Scientific (NYSE:), Abbott Laboratories (NYSE:) and Abbvie (NYSE:). This is why I have picked the AdvisorShares Vice ETF (NASDAQ:) for this year’s Best ETFs contest. Luckily for investors who are concerned about too much direct exposure to marijuana stocks, ACT’s top three holdings... | These holdings include: Thermo Fisher Scientific (NYSE:), Abbott Laboratories (NYSE:) and Abbvie (NYSE:). Furthermore, the success of ACT’s management team is reflected in the fact that despite the general pain in many marijuana and tobacco stocks this year, the ETF is up almost 16% year to date. For investors interest... | These holdings include: Thermo Fisher Scientific (NYSE:), Abbott Laboratories (NYSE:) and Abbvie (NYSE:). This year was a peculiar one for marijuana stocks. Furthermore, the success of ACT’s management team is reflected in the fact that despite the general pain in many marijuana and tobacco stocks this year, the ETF is... |
24,797 | 2019-12-07 00:00:00 UTC | 3 Biotechs Facing FDA Approvals by Year's End | ABBV | https://www.nasdaq.com/articles/3-biotechs-facing-fda-approvals-by-years-end-2019-12-07 | null | null | Biotech investors know that simply generating some positive clinical trial data for a candidate treatment is no guarantee that the drug will make it to market. The U.S. Food and Drug Administration (FDA) looks deep before giving its approval. And when a company announces that it has received either an FDA approval lett... | Allergan shareholders voted in October in favor of the company's previously announced acquisition by AbbVie (NYSE: ABBV). The deal has yet to close, but approval of this drug should only bolster its attractiveness to AbbVie shareholders. However, after it released fresh data showing that Vascepa also helps mitigate car... | Allergan shareholders voted in October in favor of the company's previously announced acquisition by AbbVie (NYSE: ABBV). The deal has yet to close, but approval of this drug should only bolster its attractiveness to AbbVie shareholders. However, after it released fresh data showing that Vascepa also helps mitigate car... | Allergan shareholders voted in October in favor of the company's previously announced acquisition by AbbVie (NYSE: ABBV). The deal has yet to close, but approval of this drug should only bolster its attractiveness to AbbVie shareholders. Allergan awaits approval for its migraine drug The FDA is expected to weigh in any... | Allergan shareholders voted in October in favor of the company's previously announced acquisition by AbbVie (NYSE: ABBV). The deal has yet to close, but approval of this drug should only bolster its attractiveness to AbbVie shareholders. However, after it released fresh data showing that Vascepa also helps mitigate car... |
24,798 | 2019-12-06 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2019-12-06 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Anothe... | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total ret... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average ... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent s... |
24,799 | 2019-12-05 00:00:00 UTC | January 2020 Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/january-2020-options-now-available-for-abbvie-abbv-2019-12-05 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new January 2020 contracts and identified one put and one call contract of particular interest.
The put cont... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $87.50 strike highlighted in red: Considering the fact that the $87.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $80.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $87.50 strike price has a current bid of 73 cents. Below is a chart showing AB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new January 2020 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $87.50 strike highlighted in red: Conside... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.